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“Dans la vie, rien nʼest à craindre, 
 tout est a comprendre.”  
 
Marie Curie 
 
“Nothing in life is to be feared. It 
 is only to be understood.” 
 
Marie Curie 
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  
	
   I	
  
1. MECHANISMS OF PHYSIOLOGICAL VESSELS FORMATION ............................................ 1 
1.1 Formation Of Vessels In The Embryo .................................................................................... 2 
1.2 Formation Of Vessels In The Adult ......................................................................................... 3 
1.3 Molecular Mechanisms Of Angiogenesis ............................................................................... 4 
1.3.1 Vascular Endothelial Growth Factors (Vegfs) And Receptors ............................................. 5 
1.3.1.1 Vegf-A Signaling And Regulation ..................................................................................... 6 
1.3.1.2 Others Vegfs Members Signaling ..................................................................................... 9 
1.3.2 Sprouting Angiogenesis ....................................................................................................... 9 
1.3.2.1 Notch And Vegf-A Cross-Talk: Regulation Of Tip And Stalk Cells Formation ................ 12 
1.3.4 Intussusceptive Angiogenesis ........................................................................................... 14 
1.4 Vessels Maturation ............................................................................................................... 18 
1.4.1 The Role Of Pdgf/Pdgfrβ In Pericyte Recruitment. ............................................................ 19 
1.4.2 Endothelium-Perycites Cross-Talk And Its Role In Promoting Vessel Stabilization .......... 20 
 
2. ANGIOGENESIS AS A THERAPEUTIC TARGET ................................................................ 22 
2.1 The Angiogenic Therapy ...................................................................................................... 25 
2.2 The Issues With Vegf-Based Therapies For Therapeutic Angiogenesis: Total Versus 
Microenvironmental Dose. .......................................................................................................... 26 
2.3 Balanced Coordinated Co-Expression Of Vegf And Pdgf-Bb Overcomes The Limits Of 
Single Vegf-Delivery For Therapeutic Angiogenesis .................................................................. 29 
 
3. RECOMBINANT GROWTH FACTORS DELIVERY FOR THERAPEUTIC 
ANGIOGENESIS ........................................................................................................................ 32 
3.1 Fibrin As A Growth Factor Delivery System ......................................................................... 35 
 
4. AIMS OF THE THESIS .......................................................................................................... 39 
 
References ................................................................................................................................. 43 
 
5. SUSTAINED AND HIGHLY TUNABLE DELIVERY OF RECOMBINANT VEGF164 FROM 
OPTIMIZED FIBRIN MATRICES ENSURE NORMAL, STABLE AND FUNCTIONAL 
ANGIOGENESIS ........................................................................................................................ 50 
5.1 Introduction ........................................................................................................................... 51 
5.2 Materials And Methods ......................................................................................................... 54 
5.3 Results .................................................................................................................................. 66 
	
   II	
  
5.4 Discussion ............................................................................................................................ 86 
5.5 Conclusions .......................................................................................................................... 99 
References ................................................................................................................................. 90 
 
6. RECOMBINANT PDGF-BB AND VEGF164 BALANCED CO-DELIVERY FROM FIBRIN 
GEL NORMALIZES ABERRANT ANGIOGENESIS INDUCED FROM HIGH VEGF164 
CONCENTRATIONS. ................................................................................................................. 92 
6.1 Introduction ........................................................................................................................... 93 
6.2 Material And Methods ........................................................................................................... 96 
6.3 Results ................................................................................................................................ 101 
6.4 Discussion .......................................................................................................................... 114 
6.5 Conclusions And Future Perspectives. ............................................................................... 116 
References ............................................................................................................................... 117 
 
7. SUMMARY AND FUTURE PERSPECTIVES ...................................................................... 119 
References ............................................................................................................................... 125 
 
 a 
 
1. MECHANISM OF PHYSIOLOGICAL VESSELS FORMATION ................................ 1 
1.1 FORMATION OF VESSELS IN THE EMBRYO .................................................................................... 2 
1.2 FORMATION OF VESSELS IN THE ADULT ....................................................................................... 3 
1.3 MOLECULAR MECHANISMS OF ANGIOGENESIS ............................................................................. 4 
1.3.1 Vascular endothelial growth factors (VEGFs) and receptors .................................... 5 
1.3.1.1 VEGF-A signaling and regulation ................................................................................................... 6 
1.3.1.2 Others VEGFs members signaling ................................................................................................. 9 
1.3.2 Sprouting angiogenesis............................................................................................. 9 
1.3.2.1 Notch and VEGF-A cross-talk: regulation of tip and stalk cells formation ................................... 12 
1.3.4 Intussusceptive angiogenesis.................................................................................. 14 
1.4 VESSELS MATURATION .......................................................................................................... 18 
1.4.1 The role of PDGF/PDGFRβ in pericyte recruitment. ................................................ 19 
1.4.2 Endothelium-perycites cross-talk and its role in promoting vessel stabilization .... 20 
2. ANGIOGENESIS AS A THERAPEUTIC TARGET ................................................. 22 
2.1 THE ANGIOGENIC THERAPY ..................................................................................................... 25 
2.2 THE ISSUES WITH VEGF-BASED THERAPIES FOR THERAPEUTIC ANGIOGENESIS: TOTAL VERSUS 
MICROENVIRONMENTAL DOSE. ..................................................................................................... 26 
2.3 BALANCED COORDINATED CO-EXPRESSION OF VEGF AND PDGF-BB OVERCOMES THE LIMITS OF SINGLE 
VEGF-DELIVERY FOR THERAPEUTIC ANGIOGENESIS .......................................................................... 29 
3. RECOMBINANT GROWTH FACTORS DELIVERY FOR THERAPEUTIC 
ANGIOGENESIS ........................................................................................................ 32 
3.1 FIBRIN AS A GROWTH FACTOR DELIVERY SYSTEM ........................................................................ 35 
4. AIMS OF THE THESIS ........................................................................................... 39 
REFERENCES ........................................................................................................... 42 
 b 
 
 
 
  
 
 
 
1. Mechanism of physiological 
vessels formation  
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1.1 Formation of vessels in the embryo 
In vertebrates, the circulatory system is the first functional organs to arise and is 
critical in providing both oxygen and nutrient supply to the developing tissues. 
The vasculature is formed through three main cellular processes: 
vasculogenesis, angiogenesis and arteriogenesis (1). Vasculogenesis is the first 
process that gives rise to blood vessels during embryonic development and the 
vascular plexus is established before the onset of heartbeat (2). The blood 
islands in the yolk sac are the earliest site of prenatal vasculogenesis. These 
are composed of heamangioblasts, the putative common precursors of 
endothelial and hematopoietic cells (3). Angioblasts, the peripheral cells of the 
blood islands, connect to construct a primitive network composed of capillaries, 
arteries and veins. Both fibroblast growth factor- 2 (FGF-2) and vascular 
endothelial growth factor -A (VEGF-A) have a key role in the specification of 
angioblasts (2). Following assembly of primitive vessels in the early embryo, 
remodeling transforms the plexus into a hierarchically organized network of 
arteries, capillaries and veins. Arterial and venous ECs possess specific 
molecular identities from the earliest stages of cardiovascular development. 
Arterial ECs in fact express the Ephrin-B2, while the venous ECs express the 
cognate receptor EphB4 (4). After endothelial cell specification, the vascular 
plexus expands by angiogenesis (reviewed in details in paragraph 1.3), that is 
defined as the formation of new blood vessels from pre-existing ones, i.e. 
capillaries and postcapillaries venule (5). After the formation of the immature 
plexus, vessels undergo to maturation by mural cells recruitment (reviewed in 
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chapter 2), a process mediated by platelet-derived growth factor-B (PDGF-B), 
angiopoietins, and transforming growth factor-β (TGF-β) (2). 
 
1.2 Formation of vessels in the adult 
In adults, growth and remodeling of the vascular network is essential for tissue 
metabolism and wound repair. Vascular growth in the postnatal life proceeds 
mainly through angiogenesis (reviewed in paragraph 1.3), which however is not 
the only mechanism of vascular growth in the adult. It has been established that 
vasculogenesis occurs also in postnatal life, as “postnatal vasculogenesis”, 
which is de novo vessel formation by in situ incorporation, differentiation, 
migration and/or proliferation of bone marrow-derived endothelial precursor 
cells (EPCs) that can be mobilized in response to various growth factors stimuli, 
as VEGF, granulocyte monocyte- colony stimulating factor (GM-CSF), FGF-2, 
and angiopoietins. This process it has been demonstrated in several disorders, 
as hypoxic conditions or tumors (6). Arteriogenesis instead define the growth of 
functional collateral arteries from pre-existing arteriol- arterial anastomoses after 
stenosis or occlusion of a major artery. This occurs in the adult to naturally 
bypass the vascular occlusion in response to increased blood flow or shear 
stress (7). It comprises the induction of vascular wall cell proliferation and 
migration and includes wall-remodeling processes. In consequence, the 
structural enlargement of collateral arterioles to arteries proceeds as an active 
growth rather than by a passive dilation because of the altered blood pressure 
(7).  
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1.3 Molecular mechanisms of angiogenesis 
Angiogenesis is a complex multi-step process, which requires the tight 
coordination of several cell types and factors (8). It can take place by two 
different mechanisms: sprouting angiogenesis (reviewed in paragraph 1.3.2) 
and splitting angiogenesis (see paragraph 1.3.3). The process can be divided in 
two sequential phases: 1) tube formation, in which endothelial cells sense the 
angiogenic stimulus and start to proliferate, migrate and assemble the new 
vessel and 2) vascular maturation (reviewed in chapter 2), in which the new 
vessels are covered from mural cells (either pericytes or smooth muscle cells) 
and generate new extracellular matrix (9). This step is necessary to induce 
endothelium quiescence and promote vessel stabilization. Newly induced 
vessels are defined stable when they become independent from the angiogenic 
stimulus (10-12). In the past years have been discovered and characterized 
numerous angiogenic factors such as vascular VEGF, angiopoietins, TGF-β, 
FGF, hepatocyte growth factor (HGF) (13). Among them, VEGF is the most 
potent and specific growth factor. It was first identified in 1983 as a protein that 
promotes vascular leakage, called VPF, (14) but was not isolated and 
characterized. It has been isolated for the first time in 1989 from medium 
conditioned by bovine pituitary follicular cells as specific endothelial cell mitogen 
and called VEGF (15). Further cloning studies have demonstrated that VEGF 
and VPF are the same protein (16, 17).  
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1.3.1 Vascular endothelial growth factors (VEGFs) and receptors 
The VEGF family of growth factors includes five members in mammals: VEGF- 
A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor (PIGF). The VEGF 
homologues produced by Orf viruses are collectively termed VEGF-E, and a 
homologue isolated from snake venom is the VEGF-F (18). VEGFs belong to 
the platelet- derived growth- factor superfamily of secreted dimeric glycoprotein 
growth factors. The main receptors involved into the signaling cascade upon 
VEGFs binding are three tyrosine kinase receptors termed VEGFR-1 (Flt-1), 
VEGFR-2 (Flk-1), and VEGFR-3 (Flt-3). All VEGFRs have a conserved 
intracellular split tyrosine kinase domain and a series of immunoglobulin – like 
domains in the extracellular part (18). Additionally there are two co-receptors, 
Neuropilins 1 and 2 (Nrp-1 and Nrp-2), originally identified as semaphorin 
receptors that mediate repulsive signals in axon guidance (19). Binding of 
VEGF ligands to their respective receptors induces receptor homodimerization 
or heterodimerization, which activates receptor kinase activity, receptor auto-
phosphorylation and downstream signaling (18)(Fig. 1). Among the mammalian 
VEGFs, VEGF-A is the most potent and characterized angiogenic growth factor 
and plays a pivotal role both in physiological and pathological conditions. 
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Figure 1 Structure and interactions of VEGFs, VEGFRs, and their NRP co-receptors.  
The different growth factors of the VEGFs family bind to their correspondent receptors specificities 
(indicated by the arrows). Binding of the dimeric VEGF ligands stimulates receptor dimerization and 
autophosphorylation, leading to the recruitment of the downstream signaling molecules (adapted from 
(18)).  
 
1.3.1.1 VEGF-A signaling and regulation 
VEGF-A is essential for both vasculogenesis and angiogenesis. Heterozygous 
mutation of the VEGF-A gene cause embryonic lethality at day 11-12. Blood 
islands, ECs and major vessels fail to form in fact in the mutant embryo, and is 
reduced the number of red blood cells (20, 21). On the other hand, increase of a 
two-or three fold overexpression of VEGF-A from its endogenous locus results 
in severe abnormalities in hearth development and embryonic lethality (22). 
VEGF-A is an oxygen sensitive molecule and its transcription is under the 
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control of hypoxia-inducible factor (HIF)-1. HIF-1 is composed by two peptides, 
HIF-1α and HIF-1β. During normoxic conditions, HIF-1α is rapidly degraded, 
whereas in hypoxic conditions it dimerizes with HIF-1β. This complex is able to 
bind and activate a specific region of the VEGF-A promoter driving its 
transcription. Regulation of angiogenesis by hypoxia is demonstrated in many 
types of tumors or in wound healing processes (23). Furthermore, several 
growth factors, inflammatory cytokines, oncogenes and hormones have also 
been reported to induce VEGF-A gene expression (24). The human VEGF-A 
gene is composed by eight exons divided by seven introns. The VEGF-A 
molecule exists in several isoforms generated by alternative splicing events 
occurring predominantly in exons 6 and 7, encoding for two different heparin- 
binding domains. Among the different VEGF-A isoforms, VEGF-A121, VEGF-A165 
and VEGF-A189 are the forms secreted by most cell types (25). These isoforms 
differ from each other in the size of the heparin-binding domain. In fact, whereas 
VEGF-A121 lacks these domains completely and is thus completely soluble, 
VEGF-A165 and VEGF-A189 have only one or both heparin- binding regions 
respectively and display increasing affinity for the extracellular matrix. As a 
consequence, VEGF-A165 is partially soluble and is able to generate gradients of 
intermediate stepness, whereas VEGF-A189, which remains tightly bound to the 
extracellular matrix, generates very steep gradients (26). The different biological 
functions of these isoforms have been extensively characterized in vivo in the 
mouse hindbrain and in retina using isoform-specific genetic manipulations and 
VEGF-A knockout mice (27). Mice VEGF-A isoforms are one aminoacid shorter 
compared to the human but showed the same biological properties (24). Mice 
having only VEGF-A120 died soon after birth, developed severe cardiomyopathy 
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(28), and showed impaired angiogenesis characterized by a reduced vascular 
branching and increased vascular diameter. The number of endothelia filopodia 
processes was reduced and their orientation compromised. On the other hand 
mice expressing only VEGF-A188 formed ectopic and abnormally thin vessel 
branches. Only mice expressing the intermediate-binding VEGF-A164 exhibited 
the growth of a normal vessel network. Further, double heterozygous mice, 
expressing both VEGF-A120 and VEGF-A188, but not VEGF-A164, induce normal 
vessel morphogenesis as obtained with VEGF-A164 alone (27). VEGF-A binds 
VEGFR-1 and VEGFR-2 as well as Nrp-1 (fig. 1) (29). VEGFR-1 is widely 
expressed even if its kinase activity is poor. It exists as a full-length form and an 
alternative spliced, soluble form (sFlt1) (30). Both forms of the VEGFR-1 bind 
VEGF-A with higher affinity than VEGFR-2, preventing the activation of this 
receptor. Flt1-/- died at embryonic day 9 (E9.0), whereas deletion of the tyrosine 
kinase domain is compatible with vascular development (31, 32). VEGFR-2 
instead is the main VEGF-A receptor on endothelial cells, is essential for 
endothelial cell biology during development and in the adult, both in physiology 
and pathology. Mouse embryos lacking VEGF-R2 die at E8.5- 9.5 and lack 
vasculogenesis and hematopoiesis (33). Activation of VEGFR-2 from VEGF-A 
exerts several actions on endothelial cells, as proliferation, migration, 
endothelial cell survival and vascular permeability. VEGFR-2 binds VEGF-A 
with a 10-fold lower affinity than VEGFR-1 (29). VEGF-A165 additionally binds 
the co-receptor Nrp-1 through its heparin- binding domain (34) forming a ternary 
complex with VEGFR-2 (35). The formation of this complex lead to enhanced 
endothelial cell migration and survival (29). In particular, Nrp-1 has been shown 
to be essential in VEGF-A in vessel sprouting and branching (36). 
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1.3.1.2 Others VEGFs members signaling 
VEGF-B exists in two different isoform, VEGF-B167 and VEGF-B186, and 
selectively binds VEGFR-1 (fig. 1) (18). VEGF-B exerts a less pronounced role 
in the vascular system, is mainly involved in the maintenance of vessels in 
pathological conditions rather than in their formation (37). In the heart, induces 
revascularization and preserves cardiac function after myocardial infarction (38, 
39). VEGF-C and VEGF-D are mainly involved in angiogenesis and their 
binding affinities for their receptor depend on proteolytic processing of their pro-
peptides (fig. 1). In fact, only the mature forms bind VEGFR-2, and the affinity 
for VEGFR-3 increases with processing. VEGF-C/VEGF-D binding to VEGFR-3 
promote lymphatic endothelial cells proliferation (29). PIGF has been 
discovered in the placenta but is expressed also in heat and lungs; it exists in 
four isoforms (PIGF1-4) in human generated by alternative splicing, of which 
only PIGF-2 has a homologue in mice. It signals through VEGFR-1 stimulating 
angiogenesis and collateral growth in ischemic limb and hearth (18). 
 
1.3.2 Sprouting angiogenesis 
Sprouting angiogenesis is the best-characterized process of vessel growth. In 
sprouting angiogenesis, endothelial cells (ECs) are attracted by pro-angiogenic 
signals, ECs loosen their cell-cell junctional contacts, start to secrete proteases 
to degrade the extracellular matrix (ECM) and become invasive and motile to 
initiate the new blood vessel sprout (8). Only some ECs are selected to initiate 
vessel sprouting; these leading endothelial cells, the tip cells, extend numerous 
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dynamic filopodia that sense and respond to attractive or repulsive guidance 
signals in the microenvironment (40, 41).  Hence, tip cells share many 
morphological and functional similarities with the neuronal growth cones that 
guide axons (42). Endothelial stalk cells follow the tip cell, compared to the tip 
cells have a lumen, are less motile, produce fewer filopodia and are more 
proliferative. They establish the trunk of the new vessel and allow the elongation 
of the vessel (43); they also form junctions with neighboring and produce 
basement membrane components to ensure the integrity of the sprout (44). 
Once initiated, EC sprouting continues in a highly directional manner until tip 
cell connect with adjacent vessels and undergo anastomosis to form a 
continuous lumen, allowing blood flow (fig. 2) (8).  
Several signaling pathways control EC behavior during angiogenic sprouting 
including Tie2 and Notch signaling. However, the vascular endothelial growth 
factor- A (VEGF-A) is the master regulator of new blood vessel sprouting during 
development, growth and disease (9). VEGF-A guides angiogenic sprouting by 
directing tip cell migration, polarization and directional filopodia extension 
depending on its local distribution and therefore on the generation of 
extracellular gradients (40). VEGF-A stimulation of VEGFR-2 mediate also 
endothelial stalk cells proliferation, but this is regulated by the concentration of 
the VEGF-A and not by the formation of extracellular gradient (40). 
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Figure 2 Cellular mechanisms of angiogenic sprouting. 
During angiogenic sprouting, selected endothelial  “tip cells” start to secrete proteases and migrate guided 
by gradients of pro-angiogenic growth factors. During sprout elongation, tip cells are followed by 
endothelial stalk cells, which proliferate and establish the vessel trunk. Upon contact with other vessels, tip 
cell behavior is repressed and vessels fused by the process of anastomosis (adapted from (8)). 
 
A balanced correct formation of tip and stalk cells that is critical for having 
physiological sprouting angiogenesis. The best know regulator of endothelial tip 
and stalk cells specification and their ligand Dll4 and Jagged1.  
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1.3.2.1 Notch and VEGF-A cross-talk: regulation of tip and stalk cells 
formation 
Notch signaling is an evolutionarily conserved pathway among vertebrate and 
invertebrate organisms (45). ECs express multiple Notch receptors (Notch1 and 
Notch4) and transmembrane Notch ligands (Delta- like 1(Dll1), Dll4, Jagged 1 
and Jagged2) (8). Ligand binding induces two further proteolytic cleavages of 
Notch receptors. Extracellular proteases sever the Notch extracellular domain 
(NECD). The cleavage and subsequent conformation changes make Notch 
susceptible to processing by γ-secretase that releases the Notch intracellular 
domain (NICD). Following translocation of the NICD into the nucleus, the NICD 
form a complex with the transcription factor RBPj/CBF1 and Mastermind-like 
proteins to drive target genes-expression, as the basic helix-loop-helix (bHLH), 
Hairy/Enhancer of Split (Hes) and Hes-related proteins (Hey), which in turn, act 
as transcriptional regulators of further downstream genes (45). This complex 
not only activates transcription but also promotes its own turnover to prevent 
sustained Notch activation. Several studies have elucidated the crucial role of 
Notch and Dll4 in tip and stalk cell formation. Endothelial- specific inducible 
knock- out of Notch 1 or Dll4 heterozygous mutation cause excessive tip cell 
formation in mouse retinas. Further, most Notch1-deficient endothelial cells are 
in tip cell position (46). In addition, studies in mouse and zebrafish revealed that 
blocking the Notch signaling either using γ-secretase inhibitors or by disruption 
of Dll4 expression increase tip cell formation and sprouting, highlighting the role 
of Notch in suppressing the tip cell fate (47-49). VEGF interact with the Dll4/ 
Notch pathway in order to guarantee the balanced formation of tip and stalk 
cells. VEGF-A signaling through VEGFR-2 promotes tip cell induction by 
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upregulating the expression of the Notch ligand Dll4. Expression of Dll4 in 
endothelial tip cells activates Notch-1 in adjacent stalk cells to laterally inhibit tip 
cell fate and maintain the hierarchical organization of sprouting ECs (46). 
Notch-1 activation inhibits VEGFR-2 function in stalk cells, which become less 
responsive to VEGF-mediated tip cells inducing signals VEGFR-1 is 
predominantly expressed in stalk cells and involved in guidance and limiting tip 
cell formation(44). Interestingly, endothelial cells can rapidly exchange between 
the tip and stalk cell position during angiogenic sprouting in vitro and in vivo in 
the head of zebrafish, by regulating the expression level of VEGFR-2 and 
VEGFR-1 (50). The sVEGFR1 rescues vascular defects caused by VEGFR1-
deficiency, defining a role of this receptor as a decoy for VEGF-A to spatially 
control VEGFR-2 signaling (Fig. 3) (51). Furthermore, it has been proved that 
activation of VEGFR-3 by VEGF-C produced by macrophages is able to 
reinforce Notch signaling and to promote the conversion of tip to stalk cells (52). 
Opposite to Dll4, stalk cells express the other Notch ligand Jagged1. Jagged1 
also promotes tip cell formation and angiogenesis, even if Jagged1 poorly 
activates the Notch receptor. In fact, in sprouting ECs the NECD is glycosylated 
by the Fringe-family of glycosyltransferase. 
 This modification favors Notch signaling via Dll4 but represses signaling via 
Jagged1. Thus, stalk cells-restricted Jagged1 competes with Dll4 for binding to 
Notch receptors on tip cells and effectively suppress Notch signaling in tip cells. 
Consequently, in the retinal vessels of EC-specific Jagged1- knockout mice is 
impaired the formation of tip cells and vascular sprouting (53). 
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Figure 3 Molecular mechanisms of endothelial tip cell selection (Lohela M et al, Curr Opin in Biol, 
2009) 
Endothelial tip cells start sprouting by sending thin filopodia toward the VEGF-A gradient. Behind the tip 
cells, proliferating endothelial stalk cells form the lumen of the newly growing vessels. Additional factors as 
a VEGF-C/D may augment the angiogenic effects of VEGF-A. VEGF-A/ VEGFR-2 signaling enhances Dll4 
expression in tip cells. Dll4-mediated activation of Notch1 in neighboring endothelial cells inhibits tip cells 
behavior in stalk cell by downregulating VEGFR-2 and VEGFR-3 while upregulating VEGFR-1. Tip and 
stalk cells can dynamically shuffle their position by dynamically regulating VEGFRs expression (adapted 
from (18)) 
 
1.3.4 Intussusceptive angiogenesis 
Intussusception is defined as the formation of new blood vessels resulting from 
the insertion and extension of luminal tissue pillars, growing in itself (54). It was 
first described from Caduff et al in 1986 (55). The formation of intraluminal 
pillars proceeds through a multistep process (Fig. 4) (56).  It starts when the 
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endothelial walls from opposite sides of a vessel protrude into the vascular 
lumen from opposite walls. Afterwards, the inter-endothelial junctions are 
reorganized, so that a central perforation is formed in the core of the pillar. A 
trans-luminal pillar is established upon contact between these processes. This 
is subsequently invaded by supporting cells, i.e. pericytes and fibroblast, which 
start to deposit ECM into the pillar. As the pillar increases in girth, it splits the 
vascular segment into two separated new vessels (Fig. 4). There are three 
forms of intussusceptive angiogenesis, based on the phenotype, the 
intussusceptive microvascular growth (IMG), the intussusceptive arborization 
(IAR), and intussusceptive branching (IBR) (56, 57). IMG is characterized by the 
formation of numerous pillars, which promote the expansion of the capillary 
plexus. In contrast, IAR contributes to the formation of a supplying vascular 
tree, in which major arterioles, venules and capillaries are discerned. The IBR, 
is important for the optimization of the branching geometry in function of the 
tissue demands, changing the branching pattern of blood vessels or pruning the 
vascular network from superfluous vessels. Blood flow has a main role in 
regulating intussusceptive angiogenesis. It has been described splitting 
angiogenesis in response to increased blood flow in the chicken chorioallantoic 
membrane (CAM) model (58) and in the skeletal muscle (59). Sprouting and 
intussusception are two complementary modes of angiogenesis, and a 
combination of metabolic and haemodynamic factors determine whether occurs 
intussusception or sprouting. In general higher levels of shear stress lead to 
intussusceptive angiogenesis, whereas angiogenic growth factors released from 
the tissue in response to hypoxia stimulate sprouting. Intussusceptive 
angiogenesis is a process that only occurs in a pre-existing vascular network 
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that was formed either through vasculogenesis or through sprouting 
angiogenesis (60). However, intussusception is energetically and metabolically 
more effective because does not require massive cell proliferation or membrane 
degradation (61). 
 
 
Figure 4 (a-d) Three-dimensional schema illustrating the steps in the formation of transluminal 
pillars during intussuscpetive angiogenesis.  
The process begins with the protrusions of endothelial cells from opposite sides into the vessel lumen 
(a,b).  After the contact has been established (c), the endothelial bilayer becomes perforated centrally and 
a transluminal pillar is formed (d). (a’-d’) Two-dimensional representation of the phases described in (a-d). 
Endothelial cells from opposite sides of a capillary protrude into its lumen until they contact each other (a’-
c’). After the formation of the transluminal pillar, the endothelial cells than retract, and newly formed pillars 
increases in girth after invasion by fibroblasts (Fb) and pericytes (Pr), which enforce collagen fibrils (Co in 
d’) (adapted from (61)). 
 
Intussusception has been described not only in physiological but also in 
pathological conditions, as for example in tumor, where after anti-angiogenic 
treatments or radiotherapy, tumors can rapidly recover by switching from 
sprouting to intussusceptive growth (62). Besides hemodynamics forces, there 
are also molecular mechanisms regulating intussusceptive angiogenesis. 
VEGF-A, the best described angiogenic growth factor, has been demonstrated 
necessary for shear stress dependent splitting of capillaries in skeletal muscle 
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and clearly induced intussusceptive angiogenesis in the CAM (63). Recent work 
from our group demonstrated that therapeutic overexpression of two different 
VEGF doses in skeletal muscle induces new vascular networks by causing 
initial circumferential enlargement of a pre-existing vessels and associated 
endothelial cell proliferation, which were accompanied with increased blood flow 
and shear stress in the absence of migrating endothelial tip cells. The 
circumferential enlargement was followed by intussusceptive remodeling (64). 
A recent computational model created on the actual experimental findings 
defined that only a narrow range of VEGF concentrations is able to guarantee a 
correct balanced formation of tip and stalk cells, whereas high VEGF levels will 
create an oscillating-negative feedback loop, which will induce an all- stalk or an 
all-tip cell phenotype (65). Recent data from our group showed that the 
homogenous enlarged vessels induced by both two VEGF doses previously 
described (64) displayed synchronous Notch1 activation in long stretches of 
contiguous endothelial cells, which also simultaneously expressed Dll4. The 
activation is lost after the intussusceptive remodeling is completed. Using a 
computational model, it was defined that VEGF therapeutic overexpression lead 
to synchronous expression of Dll4 and Notch1 in contiguous endothelial cells by 
switching from lateral inhibition to lateral induction (66). VEGF doses and shape 
of its gradient thus determine whether Dll4/Notch1 axis is activated in an 
alternate or synchronous pattern, determining whether angiogenesis is induced 
by sprouting or by intussusception (66).  
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1.4 Vessels maturation 
Once vessels are formed, vessels need to mature to return endothelium to 
quiescence and promote vessels stabilization. The blood flow in the new lumen 
remodels vessels connections and activates the shear-stress responsive 
transcription factor Kruppel-like factor 2. Upon perfusion, oxygen and nutrient 
delivery reduces VEGF-A expression and inactivates endothelial oxygen 
sensors, together shifting endothelial behavior toward a quiescent phenotype 
(43). A fundamental feature of vessel maturation is the recruitment of mural 
cells and deposition of ECM (67). Mural cells are commonly subdivided in 
vascular smooth muscle cells and pericytes, depending on their density, 
morphology, and specific markers expression (68). Vascular smooth muscle 
cells are associated with arteries and veins around which they form multiple 
concentric layers, and are separated from ECs by a matrix. Pericytes are 
associated with the microvessels, i.e. capillaries, post-capillaries venules, and 
terminal arterioles. These cells are either solitary associated with the endothelial 
tube or form a single, discontinuous layer around it. Mature pericytes are cell 
embedded within the vascular basement membrane (BM) (69), establishing a 
direct cell-to-cell contact with ECs. They probably contribute to the BM 
deposition, since in vitro studies demonstrated that pericytes-endothelial 
interaction regulates BM assembly (70). Pericytes extend primary cytoplasmic 
processes along the abluminal surface of the endothelial tube, which usually 
span several endothelial cells and occasionally bridge neighboring capillary 
branches. Thin secondary processes extend from the primary processes, which 
are normally perpendicular in their orientation relative to the primary branches, 
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thereby partially encircling the vessel. The contacts between endothelial cells 
and pericytes are usually of peg-socket type, in which pericyte cytoplasmic 
fingers (pegs) are inserted into endothelial invaginations (pockets)(71). 
Recruitment of pericytes to the growing endothelium is controlled by the 
platelet-derived-growth-factor-BB (PDGF-BB)/ PDGF receptor (PDGFR) β. 
 
1.4.1 The role of PDGF/PDGFRβ in pericyte recruitment. 
Human PDGF was originally identified as a disulfide-linked dimer of two 
different polypeptide chains, A and B. Two other polypeptide chain, PDGF-C 
and D have been discovered more recently (72). PDGFs act via two RTKs 
(PDGFR- α and PDGFR- β) with common domain structures, including five 
extracellular immunoglobulin (Ig) loops and a split intracellular tyrosine kinase 
(TK) domain. In vivo have been demonstrated interactions of the PDGF-AA and 
PDGF-CC via PDGFR-α, and PDGF-BB via PDGFR- β (72). The ligand 
receptor/pair PDGF-B/PDGFR-β has a well-characterized role in pericytes 
recruitment. PDGF-B is secreted has a homodimer from the endothelium of 
angiogenic sprouts and in the endothelium of growing arteries, at sites where 
pericytes are actively recruited and the vSMC population is expanding (40, 73). 
Perivascular mesenchimal cells representing vascular mural cells (vSMC and 
pericytes) progenitors express instead PDGFR-β (73). PDGF-BB promotes 
recruitment of pericytes to the growing vessel, the proliferation of adjacent 
mural cells progenitors (72). PDGFRs (α as β) dimerization allows receptor 
phosphorylation on tyrosine residues in the intracellular domain auto-
phosphorylation activates the receptor kinases promoting then cell growth, 
differentiation, migration and survival. Ablation of PDGF-BB or PDGFR-β in 
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mice causes mural cell deficiency leading to widespread vascular leakage and 
perinatal lethality at E16-E19. The lack of pericytes leads to endothelial 
hyperplasia and an abnormally variable capillary diameter, revealing a negative 
control of pericytes on EC proliferation (73). Once secreted, PDGF-B is bound 
to heparan sulfate proteoglycans on the cell surface or in the ECM through its 
C-terminal retention motif. The extracellular retention of PDGF-BB is necessary 
to limit the range of action of PDGF-BB and ensure tight adhesion of pericytes 
to the vessel wall (74). Knockout of the PDGF-BB retention motif in mice results 
in defective investment of pericytes in the microvessels wall and delayed 
formation of the glomerular mesangium. Although mutants live into adulthood, 
they develop glomerulosclerosis, proteinuria and severe retinopathy (74). 
Global reduction of N-sulfated heparan sulfate proteoglycans by knockout of the 
N-deacetilase/ N-sulfotransferase-1 gene (ndst-1) attenuates signaling by 
several heparan sulfate binding growth factors, including PDGF-BB and causes 
pericytes detachment and delayed pericytes migration (75). 
 
1.4.2 Endothelium-perycites cross-talk and its role in promoting 
vessel stabilization 
Mural cell recruitment is an important step to protect new vessels against VEGF 
withdrawal and thus to promote stabilization. Newly induced vessels will be 
stable if will become VEGF-independent. Pericytes exert then their regulatory 
function on endothelial cells through both cell-to-cell contact and secreted 
signals that promote vessel stabilization. There are several molecules 
regulating the endothelium/pericytes cross-talk, of which two of the best 
characterized are angiopoietin-1 (Ang-1) and TGF-β. Ang-1 is produced by 
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mural cells; it activates its endothelial receptor Tie2 promoting pericytes 
adhesion and making vessels leakage-resistant by tightening the endothelial 
junctions (76). However, recent work demonstrates that Ang-1 is not essential 
for mural cell recruitment (77). TGF-β promotes vessels maturation by 
stimulating mural cell induction, differentiation, proliferation, migration and 
production of extracellular matrix. Loss of function of TGF-β receptor 2, 
endoglin, or activin receptor-like kinase 1 (Alk1) in mice causes vessel fragility 
in part due to impaired mural cell development (78). Thus, during these phases 
of vessel growth and maturation, changes in the local balance between pro- and 
anti-angiogenic factors, as in the blood flow may prevent vessel stabilization 
and lead to the elimination of the new vessels, a process known as vascular 
pruning. 
 
  
 
 
 
 
 
 
 
2. Angiogenesis as a therapeutic 
target  
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Several studies highlighted the important role of VEGF-A as a major actor in 
embryonic and early postnatal development of the vascular system. However, 
angiogenesis can also take place in the adult life, as for example, during wound 
healing, skeletal growth, menstrual cycle and pregnancy, which all require 
tightly regulated VEGF upregulation (79). Disregulation of VEGF-A activity and 
subsequently pathological angiogenesis is a hallmark of several pathological 
disorders. A characteristic of pathological angiogenesis in that does not reach 
resolution upon the establishment of vascular perfusion. The pathological 
angiogenic cascade in fact is persistent and unresolved and becomes driven by 
the pathological condition. In several tumors as breast, kidney, brain, cervical 
and colon cancer, levels of VEGF- A have been correlated with poor prognosis 
(18). Uncontrolled neovascularization is also associated with proliferative 
retinopathy, and increased VEGF levels were described in the humor vitreous 
and aqueous of eyes of patients affected by such pathology (79). Furthermore, 
several studies have demonstrated that age-related macular degeneration 
(AMD) is caused by neovascularization and vessels leakiness (79). Since VEGF 
has a key role in developing pathological angiogenesis, several VEGF- blockers 
have been developed for clinical use in clinical cancer and eye disease (9). 
On the other hand, insufficient vascular supply is also a cause of several 
diseases, as coronary artery disease (CAD), peripheral artery disease (PAD) 
and cerebrovascular disease. Atherosclerosis is the principal pathophysiological 
process causing ischemic disease. Treatment with anticoagulants and 
vasodilators can relieve symptoms in patients with intermittent ischemic 
symptoms but is not enough to cure such pathologies. Revascularization 
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procedures, as angioplasty, intravascular catheter mediated thrombolysis, or 
bypass surgery, are performed in patients with critical symptoms to improve 
blood circulation (80). However, many patients cannot be treated with 
conventional revascularization strategies because of a poor overall health 
status, and moreover a substantial portion of patients undergoing 
revascularization strategies does not benefit from the treatments or experience 
restenosis. 
The lack of a functional vasculature is also one of the causes of failure of tissue 
engineering approaches aimed to replace complex tissues and organs with 
artificial ones created in vitro. In fact, unlike engineered skin, cartilage or 
bladder, cell viability, optimal function and/or integration of the construct used to 
generate tissues and organs for transplantation, cannot be sustained through 
diffusion alone (81). The formation and long-term survival of blood vessels 
within a material requires the integration of biochemical and biophysical cues 
(81). Also proper vascular maturation is required for the in vivo success of 
engineered tissue (82). In the last decades therapeutic angiogenesis has 
emerged as a promising alternative strategy for treating diseases suffering 
because of insufficient vascular supply. The aim of therapeutic angiogenesis in 
fact is to stimulate blood vessel growth by delivering pro-angiogenic factors, in 
an attempt to increase blood supply for improving ischemic tissue recovery, and 
promote engraftment and survival of engineered transplanted tissue.  
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2.1 The angiogenic therapy 
Stimulation of blood vessel growth can be achieved by exogenous 
administration of pro-angiogenic factors. There are three main approaches that 
have been tested in pre-clinical settings: protein, gene and cell therapies (80). 
In protein therapies, recombinant proteins are used directly to induce the 
therapeutic effects. However, the short half-life of proteins in blood, coupled 
with the dose-limiting hypotension, have prevented the therapeutic efficacy of 
this approach into large randomized clinical trials (83). Gene therapy via non 
viral and viral vectors consists in carrying the gene construct encoding a 
therapeutic protein into the target cells (84). Initial studies were performed using 
plasmid vectors, which irrespective of the therapeutic gene involved, is simple 
and fraught of the major safety concerns. However, the efficiency of naked DNA 
uptake by muscle and cardiac cells is very poor and the maintenance of gene 
expression is short (around two weeks), thus not sufficient to exert an 
angiogenic stimulus able to generate a stable vasculature (85). The use of viral 
vectors could significantly improve the efficiency of gene delivery. Adenovirus 
have been so far the preferred vector, since can transduce at high efficiency 
both endothelial and vSMC. However, first generation adenoviral vectors are 
fraught with well-established, inflammatory and immunogenic potential, which 
raises safety concerns and limits temporal expression of the transgene (85). In 
contrast, a vector system that currently appears very suitable for gene therapy 
for cardiovascular disorders is based on AAV. These vectors presented several 
advantages, as the lack of relevant immunogenicity, the absence of an 
inflammatory response at the site of injection, the capacity to transduce cells at 
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high multiplicity of infection, and the tropism for postmitotic tissues (85). Cell- 
based therapies instead use progenitor or stem cells to promote tissue repair 
(86). Cells can also been engineered to express therapeutic proteins and thus 
induce vascular growth mainly in a paracrine manner (86). The therapeutic 
potential of bone-marrow derived endothelial progenitors, which still retain the 
ability to induce postnatal vasculogenesis (6), it has been tested in several 
clinical trial for PAD, showing some promising results, even if the effective cell 
population, isolation and processing methods must continue to be refined to 
gain a deeper understanding of the feature that define its potency (86).  
 
2.2 The issues with VEGF-based therapies for therapeutic 
angiogenesis: total versus microenvironmental dose.   
Since VEGF has a key role in inducing angiogenesis (9),  it has been tested in 
several clinical trials, however until now with disappointing results (87). 
Retrospective analyses identified several issues that undetermined the efficacy 
of those trials, particularly the difficulty to deliver a sufficient VEGF dose into the 
target tissue at safe vector doses (88, 89). In fact, the delivery of recombinant 
VEGF-A165 in patients with coronary artery diseases, did not show any efficacy, 
despite brilliant results in the pre-clinical animal models, probably due to the 
short half-life of VEGF-A protein in vivo (85). Also several large randomized 
clinical-trial using plasmid delivery of VEGF-A for patients with peripheral and 
coronary artery disease did not have therapeutic efficacy. On the other hand, 
the growth of angioma was observed in a rat infarct model after injection of a 
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VEGF-encoding plasmid (90). The induction of vascular tumour (hemangiomas) 
because of uncontrolled VEGF delivery was also reported after delivery of 
retrovirally-transduced myoblast both in skeletal muscle (91) and myocardium 
(92). Further, injection of an adenoviral vector expressing VEGF induced a 
dose-dependent angiogenic response in skeletal muscle and in other tissues 
and caused angioma formation (93, 94). In addition, intramuscular VEGF gene 
transfer using recombinant Sendai virus in animals with critical limb ischemia 
resulted in increased leakiness of blood vessels, severe edema and accelerated 
limb amputation (95). Thus, VEGF has a narrow VEGF window, in which you 
pass from low but insufficient concentration rapidly to high but toxic 
concentrations. Previous work from our group has carefully investigated the 
dose-dependent effects of VEGF in both normal and ischemic skeletal muscle, 
identifying that the microenvironmental VEGF concentration, and not the total 
dose, determine the transition from normal to aberrant angiogenesis (11, 96), as 
VEGF remains tightly bound to the ECM (26). Taking advantage of an highly 
optimized myoblast-based gene delivery platform, which is based on selection 
and creation of clonal cell populations expressing each one homogenous VEGF 
levels, it has been identified that, as shown if figure 5, clonal cell population 
within the range from ≈5 ng/106 cells/day (low VEGF) to ≈70 ng/106 cells/day 
(VEGF threshold concentration) promoted the growth of normal capillaries, and 
just above the defined threshold concentration VEGF induced the growth of 
hemangiomas (Fig. 5). Conversely, the parental polyclonal cell population 
expressing heterogeneous VEGF levels led always the formation of 
hemangiomas, even if the total dose was almost diluted to 0 (Fig. 5).  
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Figure 5 The microenviromental level of VEGF produced in muscle, and not the toal dose, determines a 
threshold between the growth of normal capillaries and hemangiomas. (adapted from (11)).  
 
The control of the microenviromental VEGF concentration has been found 
crucial in determining the therapeutic efficacy of VEGF in hindlimb ischemia 
(96). In fact, only a clonal population expressing a defined medium VEGF 
concentration just below the threshold showed therapeutic efficacy, while 
neither the parental polyclonal population nor the clonal population expressing 
low VEGF levels had a therapeutic effect in hindlimb ischemia (96). 
Therefore, direct in vivo gene therapy approaches, which generate 
heterogeneous expression levels around each transduced cells, lead to a waste 
of therapeutic window (97). 
Although uncontrolled levels and long-term expression of VEGF are dangerous 
due to serious side effects, short-term expression is insufficient for the formation 
of a stable vasculature. In fact, in a transgenic mouse model the abrogation of 
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VEGF-expression before 4 weeks led to regression of the induced vasculature 
(10). VEGF-dependence of newly induced vessels has been demonstrated also 
by injecting inducible AAVs in skeletal muscle, confirming that sustained VEGF 
expression for at least 1 month is needed to induce the formation of stable 
vessels (12). Furthermore, VEGF withdrawal by a recombinant receptor-body 
(VEGF-trap) did not cause regression of new vessels only 4 weeks after 
implantation of myoblasts expressing VEGF (11). 
 
2.3 Balanced coordinated co-expression of VEGF and 
PDGF-BB overcomes the limits of single VEGF-delivery for 
therapeutic angiogenesis 
As discussed in the previous chapters, VEGF-A is the master regulator 
angiogenesis, but growth of normal and stable blood vessels requires the 
complex interactions of multiple cell types and growth factors that are 
coordinated in time and space (68). Targeting vascular maturation is an 
attractive strategy to overtake VEGF-A limitations that become evident in the 
first generation of clinical trials. The complexity and heterogeneity of factors 
involved in vascular maturation open different strategies to target this process. 
A promising candidate is represented by the PDGF-BB, that has a key role in 
recruiting pericytes and thus in promoting vessel normalization. This was 
confirmed by recent work in our group, which taking advantage of the myoblast-
mediated gene delivery platform, demonstrated that myoblasts transduced with 
a retroviral vector carrying a bicistronic construct co-expressing VEGF-A164 and 
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PDGF-BB on a fixed ratio 1:3 promoted consistent normalization of aberrant 
angiogenesis induced from heterogeneous VEGF-A164 levels (Fig. 6) (97). 
Further, when tested in hindlimb ischemia, cells co-expressing VEGF-A164 and 
PDGF-BB stimulated the growth of stable collateral arteries without causing the 
growth of any hemangioma, whereas cells expressing only VEGF-A164 
moderately increased blood vessel perfusion without stimulating growth of 
collateral arteries (97). 
 
Figure 6 Coordinated co-expression of VEGF and PDGF-BB (VIP) in a fixed molar ratio 1:3 by a single 
bicistronic construct induced only normal and robust angiogenesis, despite of high and heterogeneous 
VEGF level (adapted from (97)).  
 
Besides, unpublished data from our group indicate that PDGF-BB co-
expression accelerates the stabilization of vessels induced by heterogeneous 
VEGF-A164 levels, so that 50% of new vessels were already VEGF- 
independent after 2 weeks, whereas none was stable when VEGF-A164 was 
expressed alone (98). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Recombinant growth factors 
delivery for therapeutic 
angiogenesis   
 33 
Cell-based delivery of angiogenic growth factors into skeletal muscle has 
allowed elucidating fundamental requirements that need to be fulfilled to induce 
therapeutic angiogenesis. However, while very useful as a controlled model 
system, this approach is not suitable for a clinical application. In fact, the 
isolation, transduction and clonal expansion of autologous cells is too expensive 
and time-consuming, while the use of retroviral vectors, which integrate in the 
host genome and can cause malignant transformation by insertional 
mutagenesis, raises safety concerns (99). The use of recombinant proteins 
presents several desirable features for clinical translation of these biological 
concepts compared to gene therapy approaches, such as the lack of genetic 
modification, the ease of achieving a homogenous dose distribution and the 
limited duration of treatment. However, soluble recombinant proteins are 
degraded rapidly and deactivated by enzymes or other chemical and physical 
degrading reactions occurring at body temperature and hence have short half-
life (100, 101). Growth factors are physiologically present either as matrix-
bound proteins attached to the ECM or as soluble molecules secreted by cells 
or cleaved from the matrix by certain enzymes or proteases. In this sense, the 
ECM serves as a reservoir of morphogenetic signals; how this reservoir 
displays or releases these signals in response to cellular influences determine 
its role in tissues homeostasis, development, and in response to injury. Also 
endothelial cell function and vascular growth are critically dependent on the 
interactions with the surrounding ECM. The ECM controls in fact endothelial cell 
activities by diverse mechanisms ranging from cell anchorage, integrin-
mediated activation and signaling to binding, release and activation of soluble 
growth factors (102). Several angiogenic growth factors as FGF, VEGF and 
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PDGF-BB are tightly bound to the heparin sulfate proteoglycans of the 
extracellular matrix. The binding of growth factors such as VEGF and PDGF-BB 
is crucial to establish concentration gradients and limits their action in vivo, 
ensuring the growth of normal blood vessels (103). Thus, polymeric materials 
mimicking the natural ECM are an interesting approach to deliver growth factors 
aiming to reproduce the physiological cell-demanded growth factor release, in 
order to create the necessary spatial and temporal gradients and regulate the 
extent and pattern of tissue formation (100). This approach would protect 
growth factors from rapid clearance, and allow controlled, sustained and 
localized delivery (100). Delivery vehicles may be fabricated from a variety of 
synthetic and natural polymers. While natural tissue-derived matrices have an 
innate capacity to interact with cells and go through cell-mediated degradation, 
synthetic matrices in their naive form lack cellular recognition but have well-
controlled and reproducible chemical properties (104). Therefore, natural ECM-
derived biomaterials have the key advantages of not requiring modifications to 
allow cell-adhesion and infiltration. Other key advantages are the relative easy 
production at low cost. Examples are collagen and fibrin that are clinically well-
established and FDA-approved matrices for wound healing to treat burns and 
chronic wounds, and as tissue sealants, respectively (104). Fibrin matrices, as 
will be reviewed in detail in the next paragraph, allow to couple modified growth 
factors enzymatically to the fibrin monomer during their cross-linking reaction 
and subsequent release from cells that are locally remodeling the matrix. This 
property allow controlled and cell-demanded growth factor release necessary to 
induce therapeutic angiogenesis, providing to fibrin compared to collagen a key 
advantage as a reservoir for pro-angiogenic growth factors (104). 
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3.1 Fibrin as a growth factor delivery system 
Fibrin is a biopolymer found in tissue repair but not in the otherwise healthy 
organism. Fibrin formation in fact occurs naturally during the blood coagulation 
cascade, and serves as a reservoir for proliferating cells and growth factors, 
degrading in synergy with tissue formation. There are three main components 
making a fibrin gel, fibrinogen, thrombin and factor XIII. When the components 
are mixed together in a calcium-enriched environment, the thrombin 
enzymatically cleaves fibrinogen to form fibrin and the factor XIII to factor XIIIa. 
Fibrin monomer then self-assembled to fibrin dimer, which are cross-linked by 
factor XIIIa through transglutaminase reaction to form the final fibrin gel (105). 
In contrast to the more permanent ECM which are usually formed by the 
sequential assembly of numerous components in a spatially ordered array that 
is difficult or impossible to reproduce in vitro, fibrin gels formed from purified 
plasma proteins acquires structures and mechanical properties that are very 
similar to those of the blood clot (106). 
There are several advantages that make fibrin a suitable material for 
regenerative medicine application, as the abundance of fibrinogen and its 
relative easy purification, the possible fine control of gelation times and 
mechanical properties of fibrin gels by adjusting the concentration of its 
components (107). 
Initial attempts to use fibrin gel as a reservoir of growth factors have been done 
by direct loading of different proteins into the gel. However, the simple mixtures 
of VEGF or FGF with fibrin gels showed release kinetics indicative of an 
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uncontrolled burst, not useful for the purpose to use them for therapeutic 
angiogenesis (108). Thus, methods for incorporation of growth factors would 
allow taking advantage of fibrin gels as materials allowing cell-demanded and 
controlled growth factor release applicable in tissue regeneration and vascular 
growth. In this direction, Schense JC et al previously developed a mechanism 
by which any number of biomolecules can be grafted within a fibrin scaffold 
during fibrinogen cross-linking (109). Specifically, they designed a bi-domain 
substrate with a factor XIIIa substrate derived from α2-plasmin inhibitor (α2-PI1-8) 
at the N-terminal and at the C-terminal the peptide or the growth factor of 
interest (Fig. 7). This domain allow covalent binding of the growth factor 
mediated from factor XIIIa cross-linking reaction of the fibrin monomer, and can 
be cleaved from cell-released proteases while they are locally remodeling the 
matrix (110). The first molecule modified using this approach was the heparin, 
which then can bind several growth factors by natural affinity. Using this 
approach, it has been demonstrated that controlled release of several nerve-
growth promoting factors could be accomplished from the heparin-laden fibrin 
matrix promoting efficient neurite growth extension compared to control (111, 
112). 
Furthermore, several recombinant fibronectin (FN) fragments have been 
synthetized as bi-domain containing the α2-PI1-8 substrate site at the N-terminal 
(113, 114). This recombinant fibronectin fragments display affinity for several 
integrins and growth factors as VEGF, PDGF-BB and BMP-2. The engineered 
FN fragment co-delivered together with VEGF and PDGF-BB in vivo 
significantly enhances wound regeneration, and further promoted bone healing 
in a critical size defect when co-delivered with PDGF-BB and BMP-2 (115). 
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 In addition to heparin and FN fragments, several growth factors also can be 
engineered to contain the α2-plasmin inhibitor (α2-PI1-8) at the N-terminal, for 
direct incorporation within the fibrin matrix, with a significant improvement of 
their biological activities (Fig. 7). The α2-PI1-8-VEGF-A121 in the CAM assay 
induced robust angiogenesis with a well-organized pattern of capillaries, 
avoiding the formation of massive edema, whereas the native form of the 
VEGF-A121 induced the growth of chaotic and abnormally enlarged vessels 
(116). This protein contained the α2-PI1-8 transglutaminase substrate domain at 
the N-terminal for the covalent binding by factor XIIIa, a central plasmin 
substrate (pl) domain that provides a further cleavage site for local cell-
mediated release, and a C-terminal human BMP-2 domain that provides the 
osteogenic properties (Fig. 7). The α2-PI1-8 –pl-BMP-2 protein loaded in fibrin 
gel significantly improved bone healing compared to WT BMP-2 (117). 
Recently, it has been generated as a recombinant protein with at the N-terminal 
the α2-PI1-8 peptide also the insulin growth factor- 1 (IGF-1) (118). This modified 
fusion protein loaded into fibrin gel applied to bladder lesions significantly 
enhances smooth muscle cells regenerative response compared to the wild 
type protein (118). 
However, the brief persistence of fibrin hydrogel, with complete degradation 
within a week (116), has been a major obstacle to the exploitation of this system 
for therapeutic angiogenesis.  
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Figure 7 Incorporation of bi-domain peptide or fusion protein into fibrin gel. Heparin bi-domain peptide or 
engineered fusion proteins have been synthetized to contain the sequence α2-PI1-8, which is the 
transglutaminase substrate, at the N-terminal, to allow covalent binding and subsequent controlled release 
mediated from cell-associated enzymatic activities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Aims of the thesis   
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Therapeutic angiogenesis is a promising strategy to treat pathologies 
characterized by insufficient blood supply to tissues, such as coronary and 
peripheral artery diseases, but also to promote the engraftment and survival of 
tissue-engineered constructs after transplantation into the host. Since the 
identification of the master regulator of angiogenesis, VEGF, many clinical trials 
have been performed but did not demonstrate clinical efficacy (87). Taking 
advantage of an optimized myoblast-based gene delivery system, our group 
previously investigated the key requirements to induce therapeutic 
angiogenesis either by VEGF-gene delivery alone or by balanced co-expression 
of VEGF and PDGF-BB from a single bicistronic construct (11, 97). However, 
while very useful as a controlled model system, this approach is not suitable for 
a clinical application. In fact, the isolation, transduction and clonal expansion of 
autologous cells is too expensive and time-consuming, while the use of 
retroviral vectors, which integrate in the host genome and can cause malignant 
transformation by insertional mutagenesis, raises safety concerns (99). 
The delivery of recombinant growth factors presents several desirable features 
for clinical translation of these biological concepts compared to gene-therapy, 
such as a defined duration of treatment, homogenous dose distribution and the 
absence of genetic modifications. However, the very short half-life of 
recombinant growth factors after direct injection in vivo has limited their clinical 
usefulness. The controlled release of factors from biopolymers is an attractive 
approach to protect them from rapid clearance while ensuring homogenous and 
sustained release (119). 
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Pro-angiogenic factors such as VEGF and PDGF-BB have heparin-binding 
domains that localize them in the extracellular matrix after secretion and their 
restricted spatial organization within the microenvironment is crucial to induce 
physiological angiogenesis (103). Therefore, the group of J. Hubbell (EPFL, 
Lausanne, Switzerland) previously developed a protein engineering approach 
that enzymatically links recombinant growth factors to fibrin, a biopolymer 
physiologically degraded by cell-associated proteases (105). Engineered factors 
are produced as fusion proteins with the factor XIIIa substrate sequence α2-P1-8 
(NQEQVSPL) at the N-terminal, to allow covalent binding by factor XIIIa during 
the fibrin cross-linking reaction and subsequent release by enzymatic cleavage 
(99). However, the short persistence of fibrin hydrogels in vivo (116), which did 
not allow sufficiently prolonged factor release to achieve stabilization of newly 
induced angiogenesis, has been a major obstacle towards the application of this 
approach for therapeutic angiogenesis (119). 
Therefore, the focus of this thesis is to determine the requirements to induce 
safe, stable and controlled angiogenesis by controlled delivery of recombinant 
angiogenic growth factors from fibrin gels. To this end, we investigated two 
specific aims: 
1) In aim 1, we developed an optimized fibrin platform to ensure controlled and 
dose-dependent delivery of α2-PI1-8-VEGF164 over at least 4 weeks, capable of 
inducing normal, stable and functional angiogenesis. 
2) In aim 2, we tested the hypothesis that co-delivery of α2-P1-8-VEGF164 α2-P1-8-
PDGF-BB from fibrin gels could both normalize aberrant angiogenesis induced 
by high VEGF doses and accelerate vascular stabilization after short-term 
VEGF delivery. 
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ensure normal, stable and 
functional angiogenesis. 
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5.1 Introduction 
Therapeutic angiogenesis is an attractive strategy for treating several ischemic 
conditions, such as peripheral and coronary artery diseases or chronic wounds, 
in which the intrinsic capacity for spontaneous vascular repair and tissue 
regeneration is either compromised or insufficient to restore physiological blood 
flow. Vascular endothelial growth factor (VEGF) is the master regulator of both 
physiological and pathological vascular growth (1). However, initial clinical trials 
of VEGF gene delivery with a variety of gene therapy vectors failed to establish 
clinical benefit (2). Retrospective analyses identified several issues that 
undermined the efficacy of those trials, particularly the difficulty to deliver a 
sufficient VEGF dose into the target tissue at safe vector doses (3, 4). Taking 
advantage of a highly controlled cell-based gene delivery platform, we 
previously identified a key requirement to optimize therapeutic efficacy of VEGF 
gene delivery. In fact, VEGF binds tightly to extracellular matrix (5) and induces 
normal or aberrant angiogenesis depending on its localized concentration in the 
microenvironment around each producing cell in vivo, rather than its total dose 
(6). However, it is challenging to achieve homogeneously distributed expression 
levels in vivo with gene therapy vectors. Further, newly induced vessels require 
that VEGF stimulation be sustained for at least 4 weeks in order to stabilize and 
persist indefinitely (6-8). 
The use of recombinant VEGF presents several desirable features for clinical 
translation of these biological concepts compared to gene therapy approaches, 
such as the lack of genetic modification, the ease of achieving a homogenous 
dose distribution and the limited duration of treatment. A limitation towards the 
 52 
clinical application of recombinant VEGF is its short half-life in vivo and the 
controlled release from biodegradable matrices is an attractive approach to 
protect VEGF from rapid clearance, while ensuring homogenous and sustained 
delivery (9). 
Physiological angiogenesis crucially depends on a spatially restricted 
organization of growth factor cues through their binding to the extracellular 
matrix (ECM)(10). Therefore, we previously developed a protein engineering 
approach that links growth factors to a fibrin matrix by enzymatic reaction. In 
fact, fibrin is a natural product of blood coagulation, is injectable as a liquid and 
solidifies in situ without cytotoxicity, can be remodeled by cell-associated 
enzymes, and naturally serves as a cell infiltration matrix, thereby providing 
unique features as a platform for physiological presentation of angiogenic 
signals (11). Growth factors are engineered to contain the peptide sequence α2-
P1-8 (NQEQVSPL), which is a substrate for the coagulation transglutaminase 
factor XIIIa, so that the recombinant factor is covalently incorporated into the 
fibrin matrix formed by the factor XIIIa-mediated cross-linking reaction of 
monomeric fibrinogen and it is subsequently released only through matrix 
degradation by local cell-associated proteases (12). We have previously shown 
that matrix-bound presentation of diverse so-engineered growth factors, such as 
VEGF-A121, BMP-2 and IGF-1, can considerably accentuate their biological 
effects respect to the wild type growth factors (13-15). However, the brief 
persistence of fibrin hydrogels in vivo, with complete degradation within less 
than a week (13), is insufficient to ensure the stabilization of newly induced 
vessels and is a major obstacle to its exploitation for therapeutic angiogenesis 
(16). Therefore, here we aim to develop an optimized fibrin-based platform for 
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controlled and sustained delivery of α2-P1-8-VEGF-A164 to robustly induce 
normal, stable and functional angiogenesis in therapeutically relevant target 
tissues. 
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5.2 Materials and Methods 
Recombinant α2PI1-8-VEGF164 production and purification 
The cDNA for mouse VEGF-A164 was PCR-amplified using primers designed to 
allow for fusion of the transglutaminase substrate sequence, NQEQVSPL (α2-
PI1-8), onto the N-terminus of the amplified cDNA before insertion into the 
expression vector pRSET (Invitrogen Life Science, Basel, Switzerland). The 
fusion protein was expressed into E.coli strain BL21 (Dε3) pLys (Novagen, 
MerckKGaA, Darmstad, Deutschland). The recombinant α2-PI1-8-VEGF-A164 
was isolated from inclusion bodies processed and refolded using a slightly 
modified version of a previously published protocol (17). Briefly, the inclusion 
bodies were collected from the bacterial lysate by centrifuging, washed with 
triton X-114 to remove membrane proteins and endotoxins, and extracted with 
urea buffer overnight at 4 °C under magnetic steering. Further dimerization of 
α2-PI1-8-VEGF-A164 was done with a redox system (0.5 mM oxidized glutathione, 
5 mM reduced glutathione) added into the protein solution after the 2 M urea 
dialysis and α2-PI1-8-VEGF-A164 was dimerized under stirring for 48 h at 4°C. 
Then, glutathione and urea were removed by 3 sequential dialyses of 24 h 
against Tris buffers. Proteins were then concentrated using a 10 kD Amicon 
tube (Millipore, MerckKGaA, Darmstad, Deutschland) and further filtered 
through a 0.22 μm filter.  α2PI1-8-VEGF164 monomers and dimers were 
separated using size exclusion with a HiLoad 16/60 superdex 75 pg column (GE 
healthcare, Munich, Germany). Fractions corresponding to VEGF dimers were 
pulled together, concentrated with Amicon tube, and filtered through a 0.22 um 
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filter. VEGF dimers were verified as >99% pure by SDS-PAGE and MALDI-TOF 
analysis. Endotoxin level was verified as under 0.05 EU/mg of protein using LAL 
assay (GenScript, Aachen, Germany).  
 
Fibrin gel preparation 
Fibrin matrices were prepared by mixing human fibrinogen (plasminogen-, 
von Willebrand Factor-, and fibronectin-depleted; Enzymes Research 
Laboratories, Swansea, UK), factor XIIIa (CSL Behring, Switzerland) and 
thrombin (Sigma Aldrich, St Louis, Buchs, Switzerland) combined at different 
concentrations as described in the results section with 2.5 mM of Ca2+ (Sigma 
Aldrich, St Louis, Buchs, Switzerland) in 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) (Lonza, Basel, Switzerland). Matrices 
containing aprotinin-α2-PI1-8 and α2-PI1-8-VEGF164 were obtained by adding 
them to the cross-linking enzymes solution before mixing with fibrinogen. 
Matrices were allowed to polymerize at 37 °C for 1 hour before use or directly 
injected after mixing to have in situ polymerization, depending on the 
experimental design. 
 
Determination of α2-PI1-8-VEGF-A164 release profile  
Fibrin matrices of 50 μl volume were generated with 10 mg/ml fibrinogen, 2 
U/ml of thrombin, 5 U/ml factor XIIIa , 5 mM calcium chloride, and 10 μg/ml of 
VEGF-A164 (R&D Systems, Abingdon, UK) or α2-PI1-8-VEGF164, as previously 
described (13). Fibrin gels were polymerized at 37°C for 1 h and transferred into 
24 well plate containing 500 ml of washing buffer. The 100% release control 
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well contained only the growth factor in buffer. Each 24 h, buffers were 
collected, stored at -20°C and replaced with fresh buffer. For the 100% release 
control well, 20ml of buffer was taken out every day and stored at -20°C. After 7 
days, growth factor cumulative release was quantified using ELISA using the 
100% released control as reference (DuoSet, R&D Systems, Abingdon, UK).  
 
VEGFR-2 phosphorylation assay 
HUVECs (PromoCell, Heidelberg Germany) were seeded in 96 well-plate 
(3000 cells/well) and starved 4 h with serum-free MCDB-131 medium 
(Invitrogen, Basel, Switzerland). Cells were then stimulated with 50 ng/mL of 
VEGF-A164 or α2-PI1-8-VEGF-A164 for 5 min. Phosphorylated VEGFR-2 was 
quantified using phospho-ELISA kits. Briefly, ELISA plates were coated with a 
capture antibody for the GF-receptors and then incubated with cell lysates. The 
phosphorylation state was detected with an anti-phospho-tyrosine antibody and 
normalized to a standard according to manufacturer instructions (phospho-
VEGF R2/KDR, DuoSet IC; R&D Systems, Abingdon, UK). 
 
In vitro gel polymerization 
Fibrin matrices of 50μl volume were prepared onto a plastic mini-tray (Nunc 
Microwell Minitrays, Cat. No 470378, Sigma Aldrich, St Louis Buchs 
Switzerland), placed on ice according to the compositions described in Table 1. 
The fibrinogen solution was first deposited into the well with a pipette tip, 
avoiding the formation of bubbles, and then the cross-linking enzymes were 
added. Solutions were mixed three times with the pipette to guarantee 
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homogenous mixing. The start of polymerization was defined by the change of 
consistency from liquid to stiff as detected by touch with the pipette tip. For each 
gel composition three replicates were assessed and results (in s) are presented 
as mean ± SEM. 
 
Rheology studies 
Fibrin gel discs of 1 mm thickness were pre-formed into press-to-Seal 
silicone isolator slides (P24744 Invitrogen-Molecular Probes, Basel, 
Switzerland) coated with parafilm at room temperature. The gel compositions 
tested are described in Table 2. Gels were allowed to polymerize for 1h at 37°C, 
removed from the support and placed in PBS overnight at 4 °C to allow swelling. 
Gel stiffness was determined by performing small-strain oscillatory shear 
rheometry using a Bohlin CVO 120 high-resolution rheometer with plate-plate 
geometry at room temperature (Instrumat SA, Renens, Switzerland). Gels were 
sandwiched between the two plates of the rheometer with compression up to 
80% of their original thickness to avoid slipping. Measurements were then 
conducted in a constant strain (0.05) mode as a function of frequency (from 0.1 
to 10 Hz) to obtain dynamical spectra (n=3 per condition). Results (in KPa) are 
presented as mean ± SEM. 
 
Intramuscular fibrin gel implantation in vivo 
The protocol used for the preparation of fibrin matrices was the same 
described in the section fibrin gel preparation. In order to avoid an 
immunological response to human fibrinogen and cross-linking enzymes, 6-8 
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week-old immunodeficient SCID CB.17 mice (Charles River Laboratories, 
Sulzfeld, Germany) were used. Animals were treated in accordance with the 
Swiss Federal guidelines for animal welfare, after approval from the Veterinary 
Office of the Canton of Basel-Stadt (Basel, Switzerland). A liquid volume of 50μl 
was aspirated rapidly with a 0.3 ml insulin syringe with integrated 30 G needle 
(Micro-Fine Cat. No. 320837, Becton Dickinson, Allschwil, Switzerland) and 
injected into the gastrocnemius (GC) muscle of the mice previously 
anesthetized with 3% isofluorane. After injection, in situ polymerization was 
allowed for 20 seconds before slowly extracting the needle.  
 
In vivo multispectral imaging 
Fibrin gels were prepared as described in the section fibrin gel preparation, 
but fluorescently conjugated fibrinogen (Alexa 647, Invitrogen, Basel, 
Switzerland) was inserted in a concentration of 0.5 ng/ml in the gel volume to 
monitor the degradation of the different fibrin gel compositions in vivo by non-
invasive multispectral imaging. The experiments were performed at the Ludwig 
Boltzmann Institute (Vienna, Austria) after approval by the local ethical 
committee. Animals were treated according to the National Institute of Health 
guidelines. Carprofen (2.5 mg/kg Rimadyl, Pfizer, Austria) was administered to 
animals preoperatively and for the following 3 days to ensure proper analgesia. 
A liquid volume of 50 μl was injected subcutaneously next to the spine and into 
GC muscles bilaterally in nude mice (n=10/ group). The fluorescence of the 
fibrin matrix was non-invasively followed and quantified over a period of 9 days 
using a multispectral imaging system (Maestro Imaging System, CRI Inc.,Brunn 
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am Gebirge, Austria). ROIs were defined and analyzed. The signals (counts/s) 
were normalized to day 1 values and expressed as their percentage. Data are 
represented as mean fluorescence intensity ± SEM. 
 
Histological analyses  
Mice were euthanized by vascular perfusion of 1% paraformaldehyde (Sigma 
Aldrich, St Louis Buchs, Switzerland) in PBS (Sigma Aldrich, St Louis Buchs, 
Switzerland) pH 7.4 for 3 minutes under 120 mm/Hg of pressure. 
Gastrocnemius muscles were harvested, post-fixed in 0.5% paraformaldehyde 
(PFA) in PBS pH 7.4 for 2 h at room temperature and cryoprotected by infusion 
in 30% sucrose (Sigma Aldrich, St Louis Buchs, Switzerland) in PBS at 4 °C 
overnight. Muscles were then embedded in OCT compound (CellPath, 
Newtown, Powys, UK), frozen in freezing isopentane and cryosectioned. Tissue 
sections were stained with H&E to verify the intramuscular localization of the 
gel. Vascular morphology was analyzed by immunofluorescence staining on 
12μm-thick frozen sections cut across the longitudinal axis. The following 
primary antibodies and dilutions were used: rat anti-CD31 (clone MEC 13.3, BD 
Bioscences, Basel, Switzerland) at 1:100; mouse anti-α-SMA (clone 1A4, Sigma 
Aldrich, St Louis Buchs, Switzerland) at 1:400; rabbit anti-NG2 (Merck Millipore, 
Darmstadt, Germany) at 1:200. Fluorescently labeled secondary antibodies 
(Invitrogen, Basel, Switzerland) were used at 1:200. Fluorescence images were 
taken with a 40X objective on a Carl Zeiss LSM710 3-laser scanning confocal 
microscope (Carl Zeiss, Feldbach, Switzerland). In some experiments the 
amount of undegraded gel was assessed histologically by immunostaining with 
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a primary antibody that specifically recognizes fibrin, but not fibrinogen (mouse 
anti-human fibrin, clone E8, Beckman Coulter, CA, USA) at a dilution of 1:200. 
Tissue sections were obtained at 250-μm intervals, in 3 muscles/group. Images 
were taken in each section where gel was detectable with a 10X objective on an 
Olympus BX61 fluorescence microscope (Olympus, Volketswil, Switzerland) 
and merged using the multiple image alignment (MIA) function of the CellP 
imaging analysis software (Olympus, Volketswil, Switzerland) to reconstruct the 
total area of the tissue section in which the undegraded gel was present. The 
total surface area occupied by undegraded gel was quantified (in mm2) using 
ImageJ software as the sum of all sections in each analyzed muscle. In some 
experiments, physiological perfusion of induced vessels was assessed by 
intravascular staining with a fluorescently labeled Lycopersicum esculentum 
(tomato) lectin (Vector Laboratories, Burlingame, CA, USA) that binds the 
luminal surface of blood vessels, as previously described (18). Briefly, mice 
were anesthetized and lectin was injected intravenously (50μl of a 2 mg/ml 
lectin solution per mouse) and allowed to circulate for 4 min before vascular 
perfusion of 1% PFA in PBS pH 7.4 for 3 minutes under 120 mm/Hg of 
pressure. 
 
Vessel quantifications 
Vessel diameters and vessel length density were measured in muscle frozen 
sections after staining for CD31, NG2 and SMA as previously described(6, 18).  
Briefly, vessel diameters were measured by overlaying captured microscopic 
images with a square grid. Squares were selected randomly and the diameter of 
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each vessel, if present, in the defined square was measured (in µm). Around 
500 total diameter measurements were obtained from 3 independent muscles 
for each group (n=3). Vessel length density was measured in 5-10 fields per 
muscle from 3 muscles per group (n=3) by tracing the total length of vessels in 
each field and dividing it by the area of the field (mm of vessel length/mm2 of 
surface area). All analyses were performed using the Cell P imaging software 
(Olympus, Volketswil, Switzerland). Results are presented as mean ± SEM. 
 
Subcutaneous fibrin gel implantation 
All animal procedures were approved by the Cantonal Veterinary Office of 
Canton Vaud. Female nude mice were used at about 4-5 weeks of age. Animals 
were anesthetized with inhalation of 2% isofluorane. Dorsal skin was disinfected 
with 70% ethanol. Two incisions, approximately 1.5 cm long, were made along 
the left and right sides of the dorsum. A 10-0 Dafilon suture (Braun, 
Meinsungen, Germany) was placed through each fibrin gel pellet to fasten the 
gel to the subcutaneous area just beneath the skin. Four gels of 20μl volume 
were implanted in each mouse in a random order and wounds were closed with 
7-0 Prolene sutures (Ethicon, Norderstedt, Germany). Animals were euthanized 
14 days later by carbon dioxide asphyxiation. Gels were excised together with 
the surrounding skin and samples were stored at -80°C for further analysis. 
 
α2-PI1-8-VEGF-A164 protein extraction and quantification 
The concentration of α2-PI1-8-VEGF164 in the gels after in vivo implantation 
was measured from explanted and frozen fibrin gels. They were washed in PBS 
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for 8 h at 4°C, changing the PBS every hour. Afterwards, 50 mU of plasmin 
(Sigma Aldrich, St Louis Buchs Switzerland) in 50 μl of deionized water were 
added to each gel and incubated at 37 °C on a shaker at 1000 rpm. After 8h the 
plasmin solution was renewed and incubation at 37 °C on a shaker continued 
until all gels were completely dissolved (approximately 48 h). The amount of 
VEGF in the resulting samples was measured using an ELISA kit (R&D 
Systems Europe, Abingdon, UK). One hundred μl of each sample was used in 
triplicate, and the assay was performed according to the manufactureʼs 
instructions. 
 
Endothelial cell proliferation assay 
Human umbilical vein endothelial cells (HUVECs) were cultured in 96-well 
plates (5,000 cells/well) in EGM-2 fully supplemented growth medium (Lonza, 
Basel, Switzerland) in 5% CO2 at 37°C. Before the proliferation assay, cells 
were starved for 6 hours with EMB-2 medium (Lonza, Basel, Switzerland) 
supplemented with 1% FCS. Stimulation was started by supplementing the 
EBM-2 medium with 50 ng of the protein-extract liberated from the gels for 72 h 
or 50 ng of recombinant VEGF protein (Peprotech, London, UK), for the 
reference control. Then, cell numbers were determined by adding 10µL of cell 
proliferation reagent (WST-1, Roche, Basel, Switzerland) to each well. After 4 
hours of incubation, absorbance of the samples was measured at 650 nm using 
a microplate reader (HT microplate, Biotek, Bad Friedrichshall, Germany). 
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Fasciocutaneous flap model treatment and analysis.  
The experiments were performed at the Ludwig Boltzmann Institute (Vienna, 
Austria), after approval by the local ethical committee. Six male Sprague 
Dawley rats per group, weighing 300-350 g (Harlan- Wilkemann), were used to 
perform the epigastric flap model as previously described (19). Briefly, the rats 
were anesthetized with ketamine (110 mg/kg) and xylazine (12 mg/kg). Prior to 
surgery a square flap of approximately 8x8 cm was delimited with a surgical 
marker. The flap was divided into three distinct vertical zones with equal size, 
the outer zone reflecting vital or ischemic areas depending which epigastric 
neurovascular bundle was ligated. In the outer zones a circle of 1.5 cm diameter 
located in the middle of the zone was additionally marked to identify the site for 
gel implantation. The marked square flap was elevated from cranial to caudal at 
the fascial plane of the abdominal muscular layer, until the entire flap was lifted 
and connected to the body of the animal only by the inferior epigastric 
neurovascular pedicles, at which time the entire flap was viable. To make half of 
the flap ischemic, the left or the right inferior neurovascular bundle was ligated 
according to a randomization protocol. The flap was then sutured back to its 
anatomical location. Thereafter, the circular wounds were created within the 
elevated flap not exceeding the fascia thus resulting in a wound complicated by 
ischemia in one vertical zone and an internal control wound on the opposite 
vertical zone. A volume of 100 μl of empty gel or of gel containing 2μg/ml of α2-
PI1-8-VEGF164 was applied into the sites according to a randomization protocol, 
allowing solidification in situ. Wounds were covered with a transparent foil 
dressing (Opsite, Smith and Nephew, England) and fixed with a second 
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dressing (Fixomull-stretch, Beiersdorf, Germany), changing them on day 1 and 
3. As an analgesic treatment, rats received 1.25 mg/kg butorphanol and 0,15 
mg/kg meloxicam 5mg/ml subcutaneously on the day of surgery and three days 
post-OP as well as 10 ml Ringer solution subcutaneously for fluid resuscitation 
on the day of surgery. Blood flow was measured by LDI (Moor Instruments Ltd., 
Devon, UK) system, preoperatively as baseline, postoperatively to assess the 
induction of ischemia, on day 3 and 7. Preoperative baseline values were set at 
100% and subsequent scans referred to these values and expressed as 
percentage of baseline. The ischemic and non-ischemic vertical zones were 
scanned and evaluated separately.  The scan modus was set at 10 ms/pixel, 
and a resolution of 256 x 256 pixels was chosen. Analyses were made by a 
software evaluation tool provided with the LDI MoorTM system (Moor Instruments 
Ltd., Devon, UK). Perfusion values were recorded as colored pixels, giving the 
color-coordinated 2-D image of the flap perfusion. The wound closure was 
evaluated by planimetric analysis. Excision wounds were traced on a 
transparent acrylic sheet post surgery, at day 3 and 7. The sheets were 
photographed with adjacent standard ruler and analyzed by planimetric software 
(Lucia G1, Version 4.8, Laboratory Imaging Ltd., Czech Republic). The 
planimetric results were expressed as a percentage of the total postoperative 
wound surface area. At day 7 postoperatively the animals were euthanized by 
an intracardial overdose of barbiturate (Nembutal®, 150mg/kg KG), and the 
entire wound areas (ischemic and non-ischemic) were excised. The specimens 
were fixed in 4% neutral buffered formalin for 24 hours followed by dehydration 
in ascending concentrations of alcohol before embedding in paraffin. Sections of 
4μm- thickness were cutted by using a rotatory microtome. H&E staining was 
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performed to analyse wound regeneration. Vascular morphology was analyzed 
by immunohistochemistry staining using the following primary antibodies: vWF 
(polyclonal rabbit anti-human, A0082, Dako, Glostrup, Denmark) at 1:100, rabbit 
anti-NG2 (Merck Millipore, Darmstadt, Germany) at 1:100, and SMA 
(monoclonal mouse anti-human, A2547, Sigma-Aldrich, St.Louis, MO) for 1h at 
room temperature or overnight at 4 °C. HRP- secondary antibodies anti-mouse 
(K4001, Dako, Glostrup, Denmark) and anti-rabbit (K4003, Dako, Glostrup, 
Denmark) were used for vWF and SMA, whereas biotinylated anti- rabbit 
(E0432, Dako, Glostrup, Denmark) was used for NG2. All the secondary 
antibodies were used at 1:200. Signals were developed using a peroxidase 
substrate kit (ImmPACTTM NovaREDTM, Vector, Burlingame, CA) or an alkaline 
phosphatase system (VECTASTAIN ABC-AP system AK-5000, Vector 
Laboratories, Burlingame, CA, USA). All images were acquired with a 40X 
objective using an Olympus BX61 microscope or an Olympus BXP80 
microscope (Olympus, Volketswil, Switzerland). Vessel diameters and vessel 
length density were quantified on samples stained for vWF using the method 
described in 5.2.10. 
 
Statistics 
Data are presented as mean ± SEM. The significance of differences was 
evaluated using analysis of variance (ANOVA) followed by the Bonferroni test 
(for multiple comparisons) or using a Mann-Whitney test (for single 
comparisons). P < 0.05 were considered statistically significant. 
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5.3 Results  
Generation of a recombinant murine VEGF164 variant, α2PI1-8 -
VEGF164. 
The recombinant murine VEGF164 protein fused to the α2-PI1-8 peptide at the 
N-terminal was produced by a method of protein engineering developed by one 
of us (J.H.) (20). The coupling efficiency of the α2-PI1-8-VEGF164 in fibrin gels of 
previously described standard composition (13) was assessed determining the 
growth factor released into buffer every 24 hours over a period of 7 days. About 
5.1±1.2% of the initially incorporated amount of α2-PI1-8-VEGF164 was released 
during the first day and this amount did not significantly increase after 7 days 
(6.9±1.2%) (Fig.1a). In contrast, the native VEGF164 was almost completely 
released already after 1 day (88.2±2.4%) (Fig.1a). The bioactivity of α2-PI1-8-
VEGF164 was determined by its ability to phosphorylate VEGFR-2 on HUVEC 
cells. As shown in Fig. 1b, the variant α2-PI1-8-VEGF164 was as effective as WT 
VEGF164 in inducing VEGFR-2 phosphorylation (Fig.1b). 
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Figure 1 Characterization of the murine fusion protein α2-PI1-8-VEGF164. 
(a) Percent cumulative release of α2-PI1-8-VEGF164 and WT VEGF164 from fibrin gel. Quantity of WT and 
variant VEGF164 was measured on buffer collected and replaced daily for 7 days using an ELISA kit. 
Values are reported as mean ± SEM; N=3. 
(b) Phosphorylation assay. Serum starved HUVEC cells were incubated with 50 ng/ml of VEGF164 or α2-
PI1-8-VEGF164 and the phosphorylated VEGF-R2 was quantified by ELISA. Values are reported as mean ± 
SEM; N=3.  
 
In vivo fibrin gel persistence as a function of composition. 
The polymerization time of different gel compositions was assessed in vitro to 
define gel compositions that would remain liquid longer than 10 seconds, which 
is the minimum time needed to allow in vivo injection in the gastrocnemius 
muscle of mice. Gels of 50μl volume were pre-formed on a plastic mini tray 
(Nunc, Microwell Minitrays) placed on ice to slow down gel polymerization as 
much as possible. Based on the results in Table 1, compositions based on a 
fibrinogen concentration of 50 mg/ml were excluded because of excessively fast 
polymerization.  
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 Gel composition  
 Fibrinogen 
(mg/ml) 
Factor XIII 
(U/ml) 
Thrombin 
(U/ml) 
Polimerization 
time (s) 
1 5 1 4 37± 2.2 
2 5 5 4 12.3± 0.5 
3 5 10 4 6.3± 0.5 
4 25 1 2 22.5± 0.4 
5 25 1 4 19.4± 0.3 
6 25 2 2 20.5± 0.4 
7 25 2 4 16.5± 0.4 
8 25 5 2 14.5± 0.4 
9 25 5 4 11.9± 0.1 
10 50 1 2 9.6± 0.6 
11 50 1 4 8.1± 1 
12 50 2 2 5.8± 0.3 
13 50 2 4 5.8± 1.1 
 
Table1. In vitro polymerization times of fibrin gels as a function of the concentrations of Fibrinogen, Factor 
XIII and Thrombin. Results (in seconds) are shown as mean±SEM; n=3. 
 
Since fibrinogen concentration determines the maximum amount of α2-PI1-8-
growth factor that can be loaded into the gel, the compositions with the highest 
fibrinogen concentration compatible with in vivo injection, i.e. 25 mg/ml, were 
selected for subsequent in vivo experiments. The stiffnesses of these gel 
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compositions were determined on swollen gels by performing small-strain 
oscillatory shear rheometry (Table 2). 
 
Cross-linking enzyme concentration 
(Fixed fibrinogen concentration = 25 mg/ml) 
 
FXIIIa (U/ml) Thrombin (U/ml) Gel stiffness (KPa) 
1 2 4.8±0.62 
1 4 5.4±1.15 
2 2 3.2±0.37 
2 4 3.7±0.17 
5 2 6.9±1.17 
5 4 6.2±1.68 
 
Table2. Determination of Fibrin gel stiffness as a function of cross-linking enzyme concentration. Results 
(in KPa) are shown as mean±SEM; n=3. 
 
In order to determine the gel composition that ensured the longest in vivo 
duration 50μl of each were injected into the GC muscle of SCID mice, and the 
amount of undegraded gel was assessed by histological analysis 4 days later. 
Gel compositions spanning the range of stiffnesses were also labeled with 
fluorescent fibrinogen and injected under the skin of the dorsum and into GC 
muscles in nude mice to monitor the in vivo daily degradation rate by non-
invasive multispectral imaging. The different gel compositions did not show 
appreciable differences either in gel persistence (Fig.2a) or degradation rate 
(Fig. 2b). Further, the amount of remaining gel did not correlate with each 
compositionʼs stiffness.  
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Figure 2 Determination of in vivo gel degradation. 
 (a) The different gel compositions were injected into the GC muscle of SCID mice and after 4 days the 
amount of remaining gel was quantified by immunofluorescence analysis of serial tissue sections, using an 
antibody that specifically recognizes fibrin, but not fibrinogen. Values are reported as mean area (mm2) ± 
SEM; N=3. 
(b) The different gel compositions made with fluorescently-labeled fibrinogen were injected subcutaneously 
next to the spine and intramuscularly into the GC muscle and the degradation was monitored in vivo daily 
for a period of 9 days by non-invasive imaging of fibrin fluorescence. Values are reported as mean ± SEM; 
N=9. 
 
Therefore, the composition with the lowest stiffness (3.2 KPa: Fibrinogen 25 
mg/ml, Factor XIII 2 U/ml, Thrombin 2 U/ml) was selected as the platform to 
investigate growth factor delivery in vivo, in order to maximize compliance and 
minimize invasiveness for host tissues. 
 
Aprotinin-α2-PI1-8 concentration determines both rate and duration of 
VEGF release. 
In order to prolong in vivo persistence of fibrin hydrogels and the duration of 
VEGF release, required for vascular stabilization, the gel composition was 
supplemented with aprotinin, which inhibits gel degradation by plasmin. An 
engineered aprotinin-α2-PI1-8 previously developed from one of us (J.H.) (21) 
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was used to allow covalent cross-linking into the hydrogels. Both the rate and 
duration of VEGF release from fibrin hydrogels are a function of the gel 
degradation rate, according to these relationships: 
Dose = α2-P1-8-VEGF164 concentration x gel degradation rate 
Duration = volume/gel degradation rate 
Therefore, since a reduction in degradation rate is expected to increase the 
duration of VEGF release, but to reduce its rate of release (i.e. the effective 
delivered dose), we first sought to determine the optimal aprotinin concentration 
that would ensure both sufficient in vivo persistence and an adequate VEGF 
release rate. Fibrin gels were prepared with 2 different concentrations of α2-PI1-
8-VEGF164, 100 μg/ml (the highest that could be incorporated without 
compromising their mechanical stability) and 25 μg/ml, in combination with 3 
different concentrations of aprotinin-α2-PI1-8, 17, 56 and 85 μg/ml, and the 
quality of induced angiogenesis, if any, was evaluated 9 days after 
intramuscular injection. As shown in Fig. 3, the negative control gels, which 
contained only aprotinin-α2-PI1-8 at the 3 different concentrations, did not induce 
any angiogenesis, whereas 100 μg/ml of α2-PI1-8-VEGF164 always induced the 
growth of aberrant vessels, with irregular morphology, enlarged diameters and 
multiple lumens, devoid of pericytes and covered with a thick layer of smooth 
muscle cells, similar to previously described angioma-like structures (6). 
However, the effects of the 4-fold lower α2-PI1-8-VEGF164 concentration of 25 
μg/ml were clearly dependent on aprotinin concentration: in fact, no 
angiogenesis was detectable with the 85 μg/ml of aprotinin-α2-PI1-8, aberrant 
angioma-like structures were induced with 17 μg/ml of aprotinin-α2-PI1-8, and an 
abundant network of morphologically normal capillaries, associated with typical 
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pericytes, was generated with 56 μg/ml of aprotinin-α2-PI1-8, even if rare 
enlarged vessels were still detectable (white asterisk in Fig. 3e).  
 
 
Figure 3 Aprotinin-α2-PI1-8 concentration determines the effective released dose of α2-PI1-8-VEGF164 
and the consequent angiogenic phenotype. 
Fibrin gels of 50μl volume were injected into the gastrocnemius muscle of SCID mice, with two different 
concentrations of α2-PI1-8-VEGF164, 100μg/ml and 25μg/ml tested in combination with three concentrations 
of aprotinin-α2-PI1-8 (17-56-85 μg/ml). Muscles were harvested 9 days later after perfusion-fixation with 
PFA 1%. Endothelial cells (CD31, in red), pericytes (NG2, in green), smooth muscle cells (α-SMA, in cyan) 
and nuclei (DAPI, in blue) were immunostained on frozen sections. Scale bar= 20μm; n=3 samples per 
group. 
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In all cases abundant residual gel was detectable in implanted muscles 9 days 
after injection (data not shown). Thus, an aprotinin-α2-PI1-8 concentration of 
56μg/ml was used in subsequent experiments to investigate the dose-
dependent effects of α2-PI1-8-VEGF164. 
 
α2-PI1-8-VEGF164 bioactivity after gel incorporation and in vivo 
implantation. 
We next determined whether the α2-PI1-8-VEGF164 could retain its bioactivity 
while incorporated into the fibrin gel and implanted in vivo, before being 
released. Gels were prepared with the highest feasible concentration of α2-PI1-8-
VEGF164 (100 μg/ml) and 56 μg/ml of aprotinin-α2-PI1-8. Gels of 20 μl volume 
were pre-formed at 37°C and implanted subcutaneously on the dorsum of nude 
mice (n=4 per group). After 2 weeks gels were explanted and frozen at –80°C, 
while gels that were frozen directly after preparation, without in vivo 
implantation, were used as controls (day 0). After two sequential digestions with 
plasmin for a total of approximately 56 h, the amount of extracted α2-PI1-8-
VEGF164 was measured by ELISA. After 2 weeks gels still contained a 
significant proportion of the amount of α2-PI1-8-VEGF164 incorporated at day 0 
(Fig. 4a). Furthermore, after 2 weeks of in vivo incubation gel-extracted α2-PI1-8-
VEGF164 was capable of inducing HUVEC proliferation as efficiently as without 
in vivo implantation (Day 0; Fig. 4b), indicating that gel incorporation effectively 
protects VEGF bioactivity despite prolonged permanence under in vivo 
conditions. The extracted factor showed a slightly reduced activity compared to 
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fresh recombinant VEGF (about 80% relative efficacy), likely as a consequence 
of the prolonged manipulations necessary for the gel extraction procedure. 
 
 
Figure 4 In vivo biological activity of α2-PI1-8-VEGF164 is preserved after 2 weeks of in vivo 
implantation. 
Fibrin gels of 20μl volume with 100μg/ml of α2-PI1-8-VEGF164 and 56μg/ml of aprotinin-α2-PI1-8 were pre-
formed in vitro and either immediately frozen at -80 °C (day 0) or implanted subcutaneously into nude mice 
(n=4 per group), explanted 2 weeks later and frozen at -80 °C (day 14). (a) Measure of the extracted α2-
PI1-8-VEGF164 by ELISA. Results are reported as mean concentration (ng/ml)±SEM; n=4. (b) The biological 
activity of the extracted α2-PI1-8-VEGF164 was determined by a HUVEC proliferation assay. Recombinant 
fresh VEGF164 was used as positive control. Results are shown as the percentage residual activity 
compared to fresh recombinant VEGF (mean± SEM); n=4. 
 
Dose-dependent angiogenesis by fibrin-bound α2-PI1-8-VEGF164. 
Since decreasing α2-PI1-8-VEGF164 concentration from 100 to 25 μg/ml 
caused a shift from completely aberrant to mostly normal angiogenesis (Fig. 3), 
we investigated whether lower α2-PI1-8-VEGF164 concentrations could reliably 
avoid aberrant vascular structures. GC muscles were injected with gels based 
on the optimized composition described above, with 56μg/ml of aprotinin-α2-PI1-
8, and loaded with a 50-fold range of α2-PI1-8-VEGF164 concentrations (5, 1 or 
0.1 μg/ml). After 9 days, all three α2-PI1-8-VEGF164 doses induced exclusively 
networks of morphologically normal and mature capillaries, associated with 
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NG2-positive and α-SMA-negative pericytes, with a clearly increased vascular 
density compared to controls (Fig.5). 
 
 
Figure 5 A wide range of α2-PI1-8-VEGF164 doses induces robust and normal angiogenesis. 
Fibrin gels loaded with 56 μg/ml of aprotinin-α2-PI1-8 and 5, 1 or 0.1 μg/ml of α2-PI1-8-VEGF164 were 
injected into the GC muscle of SCID mice. Muscles were harvested after perfusion-fixation with PFA 1% 9 
days later. Frozen sections were immunostained to detect endothelial cells (CD31, in red), pericytes (NG2, 
in green), smooth muscle cells (α-SMA, in cyan) and nuclei (DAPI, in blue). All α2-PI1-8-VEGF164 
concentrations induced the formation of a normal network of capillaries uniformly covered with pericytes 
and lacking smooth muscle cells. Scale bar= 20 μm; n=3 per group. 
 
Long-term stability of angiogenesis induced by optimized α2-PI1-8-
VEGF164 delivery. 
It has been previously shown that VEGF gene delivery needs to be sustained 
for at least 4 weeks to allow newly induced vessels to stabilize and become 
independent of further VEGF signaling (6-8). Therefore, we investigated 
whether delivery of fibrin-bound α2-PI1-8-VEGF164 by the optimized platform 
described above could be sustained long enough to allow vascular stabilization. 
Gels carrying four different concentrations of α2-PI1-8-VEGF164 (0.01, 0.1, 5 and 
100 μg/ml) were injected in GC muscles of SCID mice. In all conditions small 
amounts of undegraded gel were still detectable in implanted tissues (data not 
shown) and robust angiogenesis was present 4 weeks after implantation. 
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Similarly to the 9 days-results shown above, 100 μg/ml of α2-PI1-8-VEGF164 
generated large aberrant angioma-like structures mixed with more regular 
capillaries, which were however completely devoid of mural cell coverage, and 
both 0.1 and 5 μg/ml concentrations induced exclusively normal networks of 
pericyte-covered mature capillaries (Fig. 6a). Interestingly, the further 10-fold 
lower VEGF concentration of 0.01 μg/ml also induced efficient capillary growth, 
suggesting that normal angiogenesis can be effectively induced by a very wide 
range (at least 500-fold) of α2-PI1-8-VEGF164 concentrations from 5 μg/ml to 10 
ng/ml. 
Quantification of vessel diameters showed that all normal vessels induced by 
α2-PI1-8-VEGF164 concentrations up to 5 μg/ml had homogeneous diameter 
distributions in a narrow range, similar to normal capillaries in control tissues, 
whereas aberrant structures induced by 100 μg/ml displayed very 
heterogeneous and enlarged sizes (Fig. 6b). Interestingly, very low 
concentrations of α2-PI1-8-VEGF164 (10 and 100 ng/ml) induced vessels with the 
same average diameter as control tissue, whereas the capillaries induced by 5 
μg/ml were significantly larger (Fig. 6c, P< 0.001), although homogeneous in 
size and normal in morphology. In contrast to vessel diameters, the amount of 
angiogenesis (quantified as vessel length density) did not depend on the dose 
of α2-PI1-8-VEGF164. In fact, all α2-PI1-8-VEGF164 concentrations between 0.01 
and 5 µg/ml caused a similar 50-60% increase in vessel length density 
compared to controls (Fig. 6d, P< 0.001 or P< 0.001). 
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Figure 6 Sustained angiogenesis 4 weeks after optimized delivery of fibrin-bound α2-PI1-8-VEGF164. 
Fibrin gels loaded with 56 μg/ml of aprotinin-α2-PI1-8 and 0 (negative control), 0.01, 0.1, 5 and 100 μg/ml of 
α2-PI1-8-VEGF164 were injected into GC muscles of SCID mice. After 4 weeks muscles were harvested after 
perfusion-fixation with PFA 1%. (a) Frozen sections were immunostained to detect endothelial cells (CD31, 
in red), pericytes (NG2, in green) and smooth muscle cells (α-SMA, in cyan) were immunostained on 
frozen section. Scale bar = 20μm. (b-c) Vessel diameters were quantified in each group and their 
distribution (b) and average values (μm) (c) were calculated. (d) The amount of angiogenesis was 
quantified as vessel length density (VLD), calculated as the ratio between the total vessel length and the 
area of each measured field (mm/mm2). Results in (c) and (d) are shown as mean ± SEM; n = 3 
muscles/group; ***, P< 0.001, ** P<0.01 vs negative control. 
 
In order to assess whether α2-PI1-8-VEGF164-induced vessels had stabilized 
and achieved complete independence from exogenous VEGF, we investigated 
their persistence 3 months after gel injection. Angiogenesis was still present in 
all conditions, displaying the same morphologies as after 4 weeks (Fig. 7a), 
although no trace of the injected gels could be found anymore. The 
quantification of vessel length density confirmed that all α2-PI1-8-VEGF164 
concentrations causing normal angiogenesis (0.01 to 5 μg/ml) induced a similar 
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amount of new vessels, leading to about a 2-fold increase in vascular density 
(Fig. 7b). However, contrary to the results at 4 weeks, the amount of vessels still 
present 3 months after delivery of 100 μg/ml of α2-PI1-8-VEGF164, which induced 
aberrant angiogenesis, was significantly less than for the other 3 lower 
concentrations, which induced normal angiogenesis (Fig. 7b). A quantitative 
comparison between vessel length densities induced by the different conditions 
at 4 weeks and 3 months revealed that the normal vessels generated by all α2-
PI1-8-VEGF164 concentrations between 0.01 and 5 μg/ml were completely stable 
and even further increased, while greater than 60% of the aberrant vasculature 
induced by 100 μg/ml regressed by 3 months (Fig. 7c). 
 
 
Figure 7 Long-term stability of normal, but not aberrant, angiogenesis induced by optimized 
delivery of fibrin-bound α2-PI1-8-VEGF164. 
Fibrin gels loaded with 56μg/ml of aprotinin-α2-PI1-8 and 0 (negative control), 0.01, 0.1, 5 and 100 μg/ml of 
α2-PI1-8-VEGF164 were injected into GC muscles of SCID mice. After 3 months muscles were harvested 
after perfusion-fixation with PFA 1%. (a) Frozen sections were immunostained to detect endothelial cells 
(CD31, in red), pericytes (NG2, in green) and smooth muscle cells (α-SMA, in cyan). Scale bar= 20 μm. (b) 
The amount of angiogenesis was quantified as vessel length density (VLD), calculated as the ratio 
between the total vessel length and the area of each measured field (mm/mm2). Results are shown as 
mean±SEM; n = 3 muscles/group; *** P< 0.001 or ** P< 0.01 vs negative control, δδ P < 0.01, δ P < 0.05 
vs the 100 μg/ml condition. (c) The stabilization rate of vessels induced in each condition was calculated as 
the ratio between vessel densities 3 months and 4 weeks after gel injection (% Resistant Fraction), with a 
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value of 100% or higher indicating complete stabilization and a value lower than 100% indicating the 
amount of vascular regression between the two time-points. 
 
Newly-induced vessels by α2-Pi1-8-VEGF164 are functionally 
perfused. 
In order to determine whether newly induced vessels by α2-PI1-8-VEGF164 
were functionally connected to the circulation, their perfusion was assessed by 
injecting mice 4 minutes before sacrifice with a fluorescein-labeled tomato lectin 
(FITC-lectin), which binds to the lumen of all vessels connected to the general 
circulation. Perfused endothelial structures were identified by immunostaining 
on frozen sections as double-positive for CD31 and FITC-lectin. As shown in 
Figures 8 and 9, essentially all vessels induced by the different α2-PI1-8-VEGF164 
concentrations were functionally perfused both after 4 weeks (Fig. 8) and 3 
months (Fig. 9). Therefore, optimized delivery of fibrin-bound α2-PI1-8-VEGF164 
induced the growth of morphologically normal and mature vessels that are both 
stable and functionally perfused. 
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Figure 8 α2-PI1-8-VEGF164 induced vessels are functionally perfused after 4 weeks. 
FITC-lectin was injected intravenously into mice 4 weeks after gel injection, just before perfusion with PFA 
1% and sacrifice. Muscles cryosections were immuno-stained to detect endothelial cells (CD31, in red), 
while lectin shows in green. Perfused vessels were identified as double-positive for CD31 and FITC-lectin, 
appearing yellow in the merged image. Scale bar = 20 μm. 
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Figure 9 α2-PI1-8-VEGF164 induced vessels are functionally perfused after 3 months. 
FITC-lectin was injected intravenously into mice 3 months after gel injection, just before perfusion with PFA 
1% and sacrifice. Muscles cryosections were immuno-stained to detect endothelial cells (CD31, in red), 
while lectin shows in green. Perfused vessels were identified as double-positive for CD31 and FITC-lectin, 
appearing yellow in the merged image. Scale bar = 20 μm. 
 
Ischemic wound healing model. 
Next we tested the efficacy of optimized delivery of fibrin-bound α2-PI1-8-
VEGF164 to cause functional improvement in a rat model of ischemic wound 
healing. A full-thickness skin flap was elevated in the epigastric region, which 
was supplied by two vascular bundles, one on each side. One of the two 
vascular pedicles was ligated to create ischemic necrosis on that side, while the 
other side remained physiologically perfused and was used as normal control. 
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This model induces an area of full-thickness necrosis spanning approximately 
the distal 25% of the flap, if left untreated. A circular wound of 1.5 cm diameter 
was induced on each side in the center of the flap and following a randomization 
protocol a gel disc was applied onto each wound. Based on the results 
described in Figures 6 and 7, a α2-PI1-8-VEGF164 concentration of 2 μg/ml in the 
optimized fibrin matrix composition was used as the therapeutic condition, 
whereas an empty gel of the same composition was the negative control. 
Immunostaining for the endothelial marker von Willebrand Factor (vWF) showed 
that α2-PI1-8-VEGF164 increased the vascularization of the dermis after 7 days, 
both in non-ischemic and ischemic tissue (Fig. 10a, d, g and j). A quantitative 
analysis confirmed that treatment with α2-PI1-8-VEGF164 caused a significant 
increase in vessel length density in both non-ischemic and ischemic conditions 
(Fig. 10m-n, P=0.0002). Micro-vessels were associated with NG2-positive 
pericytes in all the groups (Fig. 10b, e, h and k), although the intensity of the 
staining was weaker for technical reasons. Furthermore, α-SMA-positive mural 
cells were found associated with both micro-vessels and small-caliber arterioles 
and venules (Fig. 10c, f, i and l, arrowheads), since, contrary to muscle tissue, 
in the skin a proportion of capillary pericytes also expresses α-SMA (22). The 
α2-PI1-8- VEGF164-treated tissues displayed a greater density of regularly 
shaped larger vessels (>15 μm) with the features of arterioles, i.e. covered by a 
regular smooth muscle layer and homogeneous in size, consistently with the 
previously described effect of VEGF to cause arteriolization of pre-existing 
vessels (23). Tissue perfusion was measured by Doppler imaging immediately 
after surgery, as well as at 3 and 7 days after gel implantation. The results 
showed that the increased vessel density in the α2-PI1-8-VEGF164-treated 
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tissues correlated with a significantly improved perfusion both in the non-
ischemic and ischemic sites by 7 days (Fig. 10o-p, P<0.05). 
 
 
Figure 10 α2-PI1-8-VEGF164 significantly improved wound regeneration in an ischemic wound-
healing model after 7 days of gel implantation. 
(a-i) Tissues were harvested 7 days after gel implantation, subsequently fixed in formalin before 
embedding in paraffin. Immunoistochemistry was performed on paraffin sections for endothelial cells 
(vWF), pericytes (NG2) and smooth muscle cells (α-SMA). Size bar= 20 μm. (m-n) The amount of 
angiogenesis was quantified as vessel length density (VLD), calculated as the ratio between the total 
vessel length and the area of each measured field. Results are shown as mean±SEM; n = 3 samples 
/group; P= 0.0002. (o-p) Measure of blood flow by Doppler imaging after arterial ligation, and at 3 and 7 
days gel post implantation. Results are shown as mean±SEM; n = 3 samples /group; * P< 0.05.   
 
In order to evaluate the functional effects of increased angiogenesis and 
perfusion in the treated tissues, healing of the wounds produced in the flaps 
was analyzed. In the non-ischemic condition, the control-treated tissue showed 
sign of very mild inflammation, with hyper/parakeratosis (Fig. 11a, arrowheads). 
There was not a clearly identifiable dermis beneath the epidermis, whereas 
bleeding areas could be detected (Fig. 11a, arrow). The underlying muscle layer 
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(Fig. 11b) was fully infiltrated by inflammatory cells and several muscle fibers 
displayed signs of partial necrosis, evidenced by infiltration of mononuclear 
inflammatory cells inside the myofiber (Fig. 11b, asterisks). α2-PI1-8-VEGF164 
treatment slightly reduced epidermal hyperplasia (Fig. 11c, arrowheads). Above 
the epidermis a layer of keratinized tissue with several apoptotic bodies was 
visible (Fig. 11c, white arrows) and the stratus corneus was partially present, 
indicating that the α2-PI1-8-VEGF164-treated tissue had reached a more 
advanced stage of regeneration of the skin physiological structure. Further, α2-
PI1-8-VEGF164 treatment reduced the inflammatory infiltrate in the underlying 
muscle layer and completely prevented myofiber damage (Fig. 11d). The control 
ischemic tissues displayed moderate hyperplasia of the epidermis (Fig. 11e, 
arrowheads), which was covered with a thick keratinized tissue full of apoptotic 
bodies (Fig. 11e, white arrows). Both the dermis and the underlying muscle 
layer were prominently infiltrated with inflammatory cells, the muscle fibers were 
completely disorganized, many were invaded by monocytes and several 
degenerative vacuoles were visible within the muscle layer (Fig. 11f, asterisks). 
In the α2-PI1-8-VEGF164-treated tissues, both epidermal hyperplasia and the 
thickness of the keratinized tissue with apoptotic bodies were reduced 
compared to controls (Fig. 11e and g). Further, α2-PI1-8-VEGF164 treatment 
reduced the inflammatory infiltrate in the muscle layer and prevented myofiber 
damage, avoiding tissue necrosis (Fig. 11f and h). Therefore, histological 
analysis showed that the treatment with α2-PI1-8-VEGF164 significantly improved 
the tissue regeneration process towards the physiological structure. 
Consistently with the histological results, the quantification of the wound healing 
rate showed that α2-PI1-8-VEGF164 promoted a significant acceleration of the 
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ischemic wound closure 7 days after gel implantation (Fig.11j, P< 0.05). Non-
ischemic wounds were also smaller both 3 and 7 days after α2-PI1-8-VEGF164 
treatment, although the differences were not statistically significant (Fig. 11i). 
 
 
Figure 11 α2-PI1-8-VEGF164 significantly improved wound regeneration in an ischemic wound-
healing model after 7 days of gel implantation.  
(a-h) Tissues were harvested after 7 days, subsequently fixed in formalin and embedded in paraffin. 
Paraffin sections were stained with Hematoxylin and Eosin, and representative images were taken to show 
the status of the epidermis (a, c, e, g) and beneath muscle layer (b, d, f, h). Size bar= 20 μm.  
(i-j) The wound healing rate was measured by planimetric analysis after 3 and 7 days, and represented as 
% of open wound. Results are showed as mean ± SEM; n= 6 samples/ group * P< 0.05.  
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5.4 Discussion 
Here we showed that fibrin-bound α2-PI1-8-VEGF164 provides a highly tunable 
platform to precisely control the VEGF dose that is delivered to tissues and to 
efficiently induce stable and functional angiogenesis. Our data indicated that 
incorporation of aprotinin-α2-PI1-8 at an optimal concentration is a key 
requirement to efficiently induce normal angiogenesis in vivo, since the same 
α2-PI1-8-VEGF164 concentration can cause disparate effects, from none to 
aberrant angiogenesis, depending on its rate of release, which is controlled by 
the aprotinin-α2-PI1-8 concentration. Under optimized conditions, which ensure a 
neither too fast nor too slow gel degradation rate, fibrin-bound α2-PI1-8-VEGF164 
could reliably induce exclusively normal and mature micro-vascular networks, 
which were stable and functionally perfused, over a very wide range (at least 
500-fold) of α2-PI1-8-VEGF-A164 concentrations. Remarkably, newly induced 
vessels did not regress for at least 3 months, whereas the implanted gels were 
almost completely consumed by 4 weeks, demonstrating that they achieved 
independence from exogenous VEGF signaling for their survival and suggesting 
that they could likely persist indefinitely. This is particularly relevant for the 
therapeutic potential of this approach, since until now one of the main limits of 
recombinant protein delivery for therapeutic angiogenesis has been the 
insufficient duration of GF release to achieve stable and persistent effects (16). 
On the other hand, aberrant angiogenesis induced by a α2-PI1-8-VEGF164 
concentration of 100 µg/ml failed to recruit physiological pericyte coverage by 4 
weeks, when gel-bound factor was still present, consistently with the described 
function of VEGF as a negative regulator of pericyte function through formation 
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of non-functional VEGFR-2/PDGFR-β complexes and consequent inhibition of 
PDGFR-β phosphorylation (24). When exogenous α2-PI1-8-VEGF-A164 became 
exhausted, more than 60% of the vascular structures induced by this 
excessively high dose disappeared, indicating that they could not stabilize 
despite sustained VEGF release for at least 4 weeks. 
The high tunability of the fibrin-bound delivery platform allowed us to span an 
extremely wide range of VEGF doses, including those determining the transition 
between normal and aberrant angiogenesis, which is a key feature for the 
design of preclinical dose-escalation studies. It should be noted that we chose 
to deliver the syngenic mouse recombinant factor mVEGF164 instead of the 
clinically used human homolog hVEGF165 because the experiments were 
performed in a mouse model and we recently found that the dose-dependent 
effects of VEGF are species-specific (25). In fact, even though hVEGF is 
similarly efficient to mVEGF in inducing angiogenesis in mouse muscle at lower 
doses, species-dependent differences in the relative activation of the respective 
receptors specifically mask the toxic effects of high doses of the human factor in 
mouse tissue. 
The concentration of α2-PI1-8-VEGF164 had not effect on the amount of 
induced vasculature, since already the lowest dose caused the maximum 
increase in vessel length density, which was maintained over a 500-fold range. 
However, the dose of α2-PI1-8-VEGF164 influenced the size of induced vessels, 
which remained unaffected by doses up to 0.1 μg/ml, but was significantly 
increased by 5 μg/ml. These results are relevant for the therapeutic potential of 
α2-PI1-8-VEGF164 delivery, as others and we have previously found that the size 
of newly induced vessels is key to determine the efficacy of therapeutic 
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angiogenesis approaches (18, 26). In fact, using a highly controlled cell-based 
VEGF gene delivery approach in a hindlimb ischemia model, we found that 
blood flow could be restored only if vessels were increased both in number and 
size, while a similar increase in number without change in size provided no 
therapeutic benefit (18). 
Based on these considerations we chose a concentration of 2 μg/ml to test 
the ability of fibrin-bound α2-PI1-8-VEGF164 delivery to induce functional 
improvement in an ischemic wound healing model. The treatment with α2-PI1-8-
VEGF164 stimulated a significant increase in normal angiogenesis, which 
significantly improved tissue perfusion both in non-ischemic and ischemic 
tissues. The angiogenic stimulus induced a significant improvement of the 
wound closure in ischemic conditions and a positive trend towards improvement 
in non-ischemic tissues. Interestingly, in control (untreated) conditions ischemia 
significantly slowed wound healing compared to normal tissue (55% vs 38% still 
open wound size by 7 days) and α2-PI1-8-VEGF164 treatment restored healing in 
ischemia to the non-ischemic level (36% still open wound size by 7 days). In 
non-ischemic tissue α2-PI1-8-VEGF164 treatment provided a further benefit (28% 
still open wound size by 7 days), but the magnitude of the difference was 
insufficient to reach statistical significance. These data suggest that, in the 
absence of ischemia, tissue repair proceeds already at physiological speed and 
increased blood flow could improve it only marginally, whereas in ischemic 
conditions impaired perfusion is the critical factor limiting wound healing and α2-
PI1-8-VEGF164 treatment may unfold its therapeutic effect. 
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5.5 Conclusions 
In conclusion, here we developed an optimized and highly tunable platform 
for controlled in vivo delivery of fibrin-bound α2-PI1-8-VEGF164, capable of 
reliably inducing normal, stable and functional angiogenesis in skeletal muscle, 
as well as improved perfusion and accelerated healing in ischemic wounds. 
Further studies should take advantage of the exquisite dose control afforded by 
this system to identify the therapeutic window of fibrin-bound α2-PI1-8-VEGF164 
for the treatment of limb and cardiac ischemia. In fact, while we found a wide 
range of VEGF concentrations that induce normal angiogenesis with equal 
efficiency, differences in the size of induced micro-vessels may produce 
significant disparities in therapeutic efficacy, which should be carefully 
determined in view of a clinical application. 
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6. Recombinant PDGF-BB and 
VEGF164 balanced co-delivery 
from fibrin gel normalizes 
aberrant angiogenesis induced 
from high VEGF164 
concentrations.  
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6.1 Introduction 
Therapeutic angiogenesis, i.e. the growth of new blood vessels promoted by 
delivery of vascular growth factors, is an attractive strategy for treating 
debilitating occlusive vascular diseases, but also to promote engraftment and 
survival of engineered transplanted tissue. Vascular endothelial growth factor 
(VEGF) is the master regulator of both physiological and pathological vascular 
growth (1). Despite the VEGF potency, results of placebo-controlled clinical 
trials of VEGF gene therapy for both peripherical and coronary artery disease 
have been unsuccessful until now (2). Retrospective analyses determined 
several issues that have not been adequately considered in the first generation 
of clinical trials and that could benefit for the therapeutic results (3, 4). Among 
these, two limitations of VEGF-based gene therapy arise from biological 
properties of the VEGF, specifically the need to control the microenviromental 
VEGF distribution in vivo to induce safe and therapeutic angiogenesis, and the 
requirement of prolonged expression for 4 weeks to avoid regression (5-7). 
VEGF is absolutely required to induce new blood vessel growth; nevertheless 
physiological growth of blood vessels is a complex multi-step process that 
requires the temporal and spatial co-ordination of different cell populations and 
cell types (1). In fact blood vessel maturation and subsequent stabilization 
depends on the coordinated cross-talk of multiple signaling pathways between 
the endothelium and pericytes (8). VEGF indeed initiate endothelial cells 
proliferation and migration to form the new tubular structures, whereas platelet-
derived growth factor –BB (PDGF–BB) expressed by the migrating tip cells 
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promotes vessels stabilization by recruiting pericytes (8). Therefore, 
combinatorial therapy based on growth factors promoting both endothelial cell 
proliferation and pericyte recruitment is an attractive strategy to overcome 
VEGF limitations that became evident in the first generation of clinical trials (9). 
Taking advantage on an highly controlled cell-based gene delivery platform, we 
recently found that the balanced co-expression of PDGF-BB with VEGF164 from 
a single retroviral bicistronic construct prevented aberrant vascular growth by 
uncontrolled VEGF levels, inducing only mature and stable capillary networks. 
Further, the balanced co-expression of PDGF-BB and VEGF significantly 
improved blood flow and collateral arteries growth in hindlimb ischemia, 
whereas cells expressing VEGF alone just modestly improved blood flow (10). 
Besides, recent data from our group indicate that PDGF-BB co-expression 
accelerates the stabilization of vessels induced by heterogeneous VEGF levels, 
so that 50% of new vessels were already VEGF-independent after 2 weeks, 
whereas none was stable when VEGF was expressed alone (11). 
The use of recombinant growth factor (GFs) for clinical application of these 
biological concepts would present several desirable aspects compared to gene 
therapy approaches, such as the lack of genetic modifications, the homogenous 
dose-distribution and the limited duration of the treatment. However, clinical 
application of GFs delivery for therapeutic angiogenesis in vivo it has been 
limited until now because of their rapid degradation. Controlled-release of 
recombinant protein through biodegradable matrices is an attractive approach 
to protect the growth factor from rapid clearance, while guarantying 
homogenous and sustained delivery (12). Pro-angiogenic factors such as VEGF 
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and PDGF-BB have heparin-binding domains that localize them in the 
extracellular matrix after secretion and their restricted spatial organization within 
the microenvironment is crucial to induce physiological angiogenesis. 
(13). Thus, we previously developed a protein engineering approach that 
enzymatically links recombinant growth factors (GFs) to fibrin (14), which is a 
convenient reservoir for growth factors, since is physiologically present during 
blood coagulation cascade, can be injected as liquid and allow solidification in 
situ without cytotoxicity, and can be degraded by cell-associated proteases that 
are naturally remodeling the matrix (15). Engineered proteins are fused with the 
factor XIIIa substrate sequence α2-P1-8 (NQEQVSPL), to allow covalent binding 
by factor XIIIa during cross-linking reaction, and subsequent release by cell-
associated proteases that are locally remodeling the matrix (16). In chapter 5, 
we demonstrated that the controlled release of α2-PI1-8-VEGF164 from an 
optimized fibrin matrix is a suitable system to induce normal, stable and 
functional angiogenesis. However, the co-delivery of α2-PI1-8-PDGF-BB with α2-
PI1-8-VEGF164 is a strategy to potentially expand the range of α2-PI1-8-VEGF164 
concentrations within which normal angiogenesis can be reliably induced and 
enhance vessels stabilization. Therefore, here we aim to determine if α2-PI1-8-
PDGF-BB co-delivery with α2-PI1-8-VEGF164 from fibrin gel can prevent aberrant 
angiogenesis induced from high α2-PI1-8-VEGF164 levels alone and promote the 
growth of mature and stable vessels. 
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6.2 Material and Methods 
α2PI1-8-proteins production and purification 
Recombinant α2-PI1-8-VEGF164 and aprotinin- α2-PI1-8 were produced as 
previously described (Sacchi et al, Chapter 1;(17)). PDGF-BB was designed to 
contain the factor XIIIa sensitive sequence derived from α2-plasmin inhibitor (α2-
PI1-8, NQEQVSPL) at the N-terminus. Sequence encoding for α2-PI1-8-PDGF-BB 
was synthetized by Genscript and subcloned into the mammalian expression 
vector pXLG (Protein Expression Core Facility, Ecole Polytechique Fédérale de 
Lausanne, Switzerland). In addition, a 6 x His tag was added at the C-terminus 
for further purification. Suspension-adapted HEK-293E cells were routinely 
maintained in serum-free ExCell 293 medium (SAFC Biosciences, Lenexa, KS, 
USA) with 4 mM glutamine as described (18). The day of transfection cells were 
resuspended at a density of 100 x 106 cells in 5 mL of RPMI 1640 medium with 
0.1% pluronic F68 (SAFC Biosciences, Lenexa, KS, USA) in a TubeSpin 
bioreactor 50 tubes (TPP, Trasadingen, Switzerland). Plasmid DNA of α2-PI1-8-
PDGF-BB (125 μg) and polyethylenimine (250 µg; 1 mg/mL in H2O; 
Polysciences, Eppelheim, Germany) were sequentially added and mixed. Seven 
days post-transfection, the cell culture medium containing α2-PI1-8-PDGF-BB 
was recovered by centrifugation at 1ʼ500 rpm for 10 min and filtered through a 
0.22 μm filtre. Medium containing α2-PI1-8-PDGF-BB was loaded into a HisTrap 
HP 5 mL column (GE Healthcare, Munich, Germany), using a ÄKTA Explorer 
(GE Healthcare, Munich, Germany). After extensive washing of the column with 
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binding buffer, α2-PI1-8-PDGF-BB was eluted with a gradient of 1 M imidazole for 
15 column volums. Fractions of proteins were analyzed by SDS-PAGE and 
those containing α2PI1-8-PDGF-BB were pulled together and further dialyzed 
against PBS overnight at 4 °C. The solution was then sterile-filtered through a 
0.22 μm filter and concentrated with Amicon tube (10 kDA cutoff, Millipore, 
MerckKGaA, Darmstadt, Germany), before storage at –80°C. The concentration 
of α2PI1-8-PDGF-BB was determined using ELISA (Human PDGF-BB DuoSet, 
R&D systems, Abingdon, UK) and the protein was verified as >99% pure by 
SDS-PAGE and MALDI-TOF. 
 
Fibrin gels preparation 
Fibrin matrices were prepared by mixing human fibrinogen at 25 mg/ml 
(plasminogen-, von Willebrand Factor-, and fibronectin-depleted; Enzymes 
Research Laboratories, Swansea, UK), factor XIIIa at 2 U/ml (CSL Behring, 
Switzerland) and thrombin at 2 U/ml (Sigma Aldrich, St Louis, Buchs, 
Switzerland) with 2.5 mM of Ca2+(Sigma Aldrich, St Louis, Buchs, Switzerland) 
in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Lonza, Basel, 
Switzerland). Matrices containing aprotinin-α2-PI1-8, α2-PI1-8-VEGF164 and α2-PI1-
8-PDGF-BB were obtained by adding the specific concentrations of them to the 
cross-linking enzymes solution. Matrices were directly injected after mixing to 
have in situ polymerization. 
 
Intramuscular fibrin gel implantation in vivo 
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Matrices were prepared as described in in the previous paragraph. In order to 
avoid an immunological response to human fibrinogen and cross-linking 
enzymes, we used 6-8 week-old immunodeficient SCID CB.17 mice (Charles 
River Laboratories, Sulzfeld, Germany). Animals were treated in accordance 
with the Swiss Federal guidelines for animal welfare, after approval from the 
Veterinary Office of the Canton of Basel-Stadt (Basel, Switzerland). A liquid 
volume of 50μl was aspirated rapidly with a 0.3 ml insulin syringe with 
integrated 30 G needle (Micro-Fine Cat. No. 320837, Becton Dickinson, 
Allschwil, Switzerland) and injected into the gastrocnemius (GC) muscle of the 
mice previously anesthetized with 3% isofluorane. After injection, in situ 
polymerization was allowed for 20 seconds before slowly extracting the needle. 
 
Histological analyses 
Mice were anesthetized and the tissues were fixed by vascular perfusion of 1% 
paraformaldehyde (Sigma Aldrich, St Louis Buchs, Switzerland) in PBS (Sigma 
Aldrich, St Louis Buchs, Switzerland) pH 7.4 for 3 minutes under 120 mm/Hg of 
pressure. GC muscles were harvested, post-fixed in 0.5 % paraformaldehyde 
(PFA) in PBS pH 7.4 for 2 h at room temperature and cryoprotected by infusion 
in 30% sucrose (Sigma Aldrich, St Louis Buchs, Switzerland) in PBS at 4 °C 
overnight. After, muscles were embedded in OCT compound (CellPath, 
Newtown, Powys, UK), frozen in freezing isopentane and cryosectioned.  
Tissue sections were stained with H&E to verify the intramuscular localization of 
the gel. Vascular morphology was analyzed by immunofluorescence staining on 
12μm-thick frozen sections of muscle tissue cut across the longitudinal axis. 
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The following primary antibodies and dilutions were used: rat anti-CD31 (clone 
MEC 13.3, BD Bioscences, Basel, Switzerland), at 1:100; mouse anti-α-SMA 
(clone 1A4, Sigma Aldrich, St Louis Buchs, Switzerland), at 1:400; rabbit anti-
NG2 (Millipore, MerckKGaA, Darmstadt, Germany), at 1:200. Fluorescently 
labeled secondary antibodies (Invitrogen, Basel, Switzerland) were used at 
1:200. Fluorescent image were taken with 40X objectives on a Carl Zeiss 
LSM710 3-laser scanning confocal microscope (Carl Zeiss, Feldbach, 
Switzerland). In some experiments, physiological perfusion of induced vessels 
was assessed by intravascular staining with a fluorescently labeled 
Lycopersicum esculentum (tomato) lectin (Vector Laboratories, Burlingame, 
CA,USA), that binds all the luminal surface of blood vessels, as previously 
described (19). Briefly, mice were anesthetized and lectin was injected 
intravenously (50μl of a 2 mg/ml lectin solution per mouse) and allowed to 
circulate for 4 min before vascular perfusion of 1% PFA in PBS pH 7.4 for 3 
minutes under 120 mm/Hg of pressure. 
 
Vessel quantifications 
Vessels diameters and length density were measured in muscle tissue 
cryosection after staining for CD31, NG2 and SMA as previously described (6, 
19).  Briefly, vessel diameters were measured by overlaying captured 
microscopic images with a square grid. Squares were selected at random, and 
the diameter of each vessel (if any) in the defined square was measured (in 
μm). Around 500 total vessels diameter measurements were obtained from 3 
independent muscles per each group (n=3).  Vessel length density was 
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measured from 5 to 10 fields per muscle and 3 muscles per each group (n=3) 
by tracing the total length of vessels in each field and dividing it by the area of 
the field (mm of vessel length/mm2 of surface area). All analyses were 
performed using the Cell P imaging software (Olympus, Volketswil, 
Switzerland). Results are presented as mean ± SEM. All the analyses were 
performed using the Cell P imaging software (Olympus, Volketswil, 
Switzerland). 
 
Statistics 
Data are presented as means ± SEMs. The significance of differences was 
evaluated using analysis of variance (ANOVA) followed by the Bonferroni test 
(for multiple comparisons). P < 0.05 were considered statistically significant.  
 101 
6.3 Results 
α2-PI1-8-PDGF-BB normalizes aberrant angiogenesis induced from 
high α2-PI1-8-VEGF164 levels 
The potential of α2-PI1-8-PDGF-BB to promote consistent normalization of 
aberrant angiogenesis was assessed in a previously defined gel composition 
(fibrinogen 25 mg/ml, factor XIII 2 U/ml, thrombin 2 U/ml) with 25 μg/ml of α2-
PI1-8-VEGF164 and 17 μg/ml of aprotinin- α2-PI1-8, which clearly induced the 
growth of aberrant vascular structures 9 days after in vivo injection (Chapter 5). 
The α2-PI1-8-PDGF-BB was inserted in a concentration ratio with α2-PI1-8-
VEGF164 1:3 for proof of the concept, since it has been previously demonstrated 
that balanced co-delivery from a single bicistronic construct in molar ratio 1:3 
was sufficient to normalize aberrant angiogenesis (10), and the quality of 
induced angiogenesis was assessed after 2 weeks. 
As shown in Fig. 1, the negative control group, which contained only aprotinin- 
α2-PI1-8, did not induce any angiogenesis. α2-PI1-8-VEGF164 per se induced the 
growth of aberrant vessels, with irregular shape and enlarged diameter, devoid 
of pericytes and covered with a thick layer of smooth muscle cells (Fig. 1b, 
asterisks), similar to previously described angioma-like structures (6). The co-
delivery of α2-PI1-8-PDGF-BB with α2-PI1-8-VEGF164 instead completely 
prevented the growth of aberrant structures and induced an abundant network 
of only normal and mature capillaries covered by NG2-positive and α-SMA-
negative pericytes (Fig. 1c). 
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Figure 1 Balanced co-delivery of α2 –PI1-8 -PDGF-BB and α2 –PI1-8 –VEGF164 from fibrin gels in a ratio 
w/w 1:3 promotes consistent normalization of aberrant angiogenesis. 
Fibrin gels of 50 μl containing 17μg/ml of aprotinin-α2-PI1-8, 25 μg/ml of α2-PI1-8-VEGF164 alone or 
combined with 8.3 μg/ml of α2-PI1-8-PDGF-BB (α2-PI1-8-PDGF-BB:α2-PI1-8-VEGF164 ratio=1:3) were injected 
into GC muscles and harvested after perfusion-fixation with PFA 1% 2 weeks later. Histological sections 
were stained for endothelial cells (CD31, in red), pericytes (NG2, in green), and smooth muscle cells (α-
SMA, in cyan) and nuclei (DAPI, in blue). Muscles were analyzed for N=3 per group. Scale bar= 20 μm.  
 
A concentration ratio α2-PI1-8-PDGF-BB: α2-PI1-8-VEGF164 1:20 is 
sufficient to normalize aberrant angiogenesis induced from high α2-
PI1-8-VEGF164 levels 
Since α2-PI1-8-PDGF-BB and α2-PI1-8-VEGF164 in concentration ratio 1:3 
induced the growth of normal and stable capillaries, we sought to determine the 
minimum concentration of α2-PI1-8-PDGF-BB necessary to consistently 
normalize aberrant angiogenesis. Gastrocnemius muscles were injected with 
gels based on the selected composition described above, with 17μg/ml of 
aprotinin-α2-PI1-8 and 25μg/ml, and a 20- fold range of α2-PI1-8-PDGF-BB 
concentrations (5μg/ml (1:5), 2.5μg/ml (1:10), 1.25μg/ml (1:20) and 0.25 μg/ml 
(1:100)). After 2 weeks, α2-PI1-8-PDGF-BB amounts as low as 1/20th of the α2-
PI1-8-VEGF164 concentration consistently normalized aberrant angiogenesis, 
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promoting the growth of normal capillaries wrapped by pericytes having the 
characteristically branches processes, with a clearly increased vascular density 
compared to control (Fig. 2, arrowheads). Conversely, reducing α2-PI1-8-PDGF-
BB down to 1/100th of the α2-PI1-8-VEGF164 concentration abolished this effect 
and caused the growth of aberrant enlarged vessels, covered by an external 
coat of smooth muscle cells, as with α2-PI1-8-VEGF164 alone (Fig. 2, asterisks) 
and pericyte naked-capillaries (Fig.2, arrows).  
 
 
Figure 2 The ratio α2-PI1-8-PDGF-BB: α2-PI1-8-VEGF164 1:20 is the minimum necessary to induce 
angiogenesis normalization. 
Fibrin gels of 50 μl containing 17μg/ml of aprotinin-α2-PI1-8, 25 μg/ml of α2-PI1-8-VEGF164 and α2-PI1-8-
PDGF-BB at a concentration of 1/5th, 1/10th, 1/20th and 1/100th of the α2-PI1-8-VEGF164 concentration were 
injected into GC muscles and harvested after perfusion-fixation with PFA 1% 2 weeks later. Frozen 
sections were immuno-stained for endothelial cells (CD31, in red), pericytes (NG2, in green), smooth 
muscle cells (α-SMA, in cyan) and nuclei (DAPI, in blue). Muscles were analyzed for N=3 per group. Scale 
bar= 20 μm 
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Co-delivery of α2-PI1-8-PDGF-BB with a two-fold higher concentration of α2-PI1-8-
VEGF164 (50μg/ml) in ratio 1:20 also completely abolished the growth of the 
angioma-like vessels induced by α2-PI1-8-VEGF164 alone (Fig. 3, asterisks) and 
promoted the growth of only normal and mature capillaries covered by pericytes 
(Fig. 3, arrowheads). This confirmed that α2-PI1-8-PDGF-BB co-delivered in ratio 
1:20 with α2-PI1-8-VEGF164 is sufficient to promote consistent aberrant 
angiogenesis normalization. α2-PI1-8-PDGF-BB injected alone did not perturb 
pre-existing angiogenesis into the skeletal muscle (Fig. 3).  
 
 
Figure 3 The ratio α2-PI1-8-PDGF-BB: α2-PI1-8-VEGF164 and not the absolute concentration of the two 
growth factors is determinant to induce normal angiogenesis.  
Fibrin gels of 50 μl containing 17μg/ml of aprotinin-α2-PI1-8, 50 μg/ml of α2-PI1-8-VEGF164 alone or co-
delivered with α2-PI1-8-PDGF-BB at 1/20th of the α2-PI1-8-VEGF164 concentration were injected into GC 
muscles and harvested after perfusion-fixation with PFA 1% 2 weeks later. Frozen sections were immuno-
stained for endothelial cells (CD31, in red), pericytes (NG2, in green), and smooth muscle cells (α-SMA, in 
cyan). Scale bar= 20 μm.  
 
Long-term stability of vessels induced by α2-PI1-8-PDGF-BB and α2-
PI1-8-VEGF164 co-delivery 
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In order to assess whether vessels induced by balanced co-delivery of α2-PI1-8-
PDGF-BB and α2-PI1-8-VEGF164 had stabilized and achieved complete 
independence from exogenous pro- angiogenic stimulus, we investigated their 
persistence 2 months after gel injection. Gels loaded with 50 μg/ml of α2-PI1-8-
VEGF164 alone or co-delivered with α2-PI1-8-PDGF-BB at 1/20th of the 
concentration, as well as 50 μg/ml of α2-PI1-8-PDGF-BB alone, were injected 
into the GC muscles of SCID mice. In all conditions no trace of the injected gels 
could be found anymore. Similarly to the 2 weeks-results shown above, α2-PI1-8-
PDGF-BB: α2-PI1-8-VEGF164 balanced co -delivery after 2 months induced 
normal capillaries wrapped by pericytes (Fig. 4a). On the other hand, α2-PI1-8-
VEGF164 alone at this time promoted the growth of only normal and mature 
capillaries, covered by pericytes, without growth of aberrant vascular structures 
(Fig. 4a). Quantification of vessels diameter showed that all the three groups, 
α2-PI1-8-VEGF164 or α2-PI1-8-PDGF-BB each one alone, or combined together, 
had homogenous diameter distributions in a narrow range, similar to normal 
capillaries in control tissues (Fig. 4b). α2-PI1-8-PDGF-BB induced vessels with 
the same average diameter as control tissue, whereas the capillaries induced 
by α2-PI1-8-VEGF164 alone or combined with α2-PI1-8-PDGF-BB where 
significantly larger, although homogeneous in size and normal in morphology. 
Interestingly, co-delivery of α2-PI1-8-PDGF-BB and α2-PI1-8-VEGF164 induced 
vessels significantly larger than those induced by α2-PI1-8-VEGF164 alone (fig. 
4c, εε P< 0.01). In contrast to vessel diameter, the amount of induced 
vasculature (quantified as vessel length density) was not increased by 2-PI1-8-
PDGF-BB co-delivery with α2-PI1-8-VEGF164 compared to α2-PI1-8-VEGF164 
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alone, since both induced about a 2-fold increase in vascular density compared 
to the negative control (Fig. 4d, ** P< 0.01, *** P< 0.001). Furthermore, α2-PI1-8-
PDGF-BB and α2-PI1-8-VEGF164 co-delivery induced a significant higher amount 
of vasculature compared to the α2-PI1-8-PDGF-BB injected alone (Fig. 4d, δ P< 
0.05). 
 
 
Figure 4 Long-term stability of angiogenesis induced by balanced co-delivery of α2-PI1-8-PDGF-BB 
and α2-PI1-8-VEGF164  
(a) Fibrin gels of 50μl volume with inserted an aprotinin-α2-PI1-8 concentration of 17μg/ml, 50 µg/ml of α2-
PI1-8-VEGF164 alone or in combination with α2-PI1-8-PDGF-BB at 1/20th of the α2-PI1-8-VEGF164 
concentration were injected into the GC of SCID mice. α2-PI1-8-PDGF-BB was tested alone in a 
concentration of 50 µg/ml to verify its angiogenic potential after 2 months. Endothelial cells (CD31, in red), 
pericytes (NG2, in green), smooth muscle cells (α-SMA, in cyan) were immuno-stained on frozen section. 
Scale bar= 20 μm 
(b-c) Vessel diameters were quantified in each group and their distribution (b) and average values (μm) (c) 
were calculated. (d) The amount of angiogenesis was quantified as vessel length density (VLD), calculated 
as the ratio between the total vessel length and the area of each measured field (mm/mm2). Results in (c) 
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and (d) are shown as mean ± SEM; n = 3 muscles/group; ***, P< 0.001, ** P<0.01 vs negative control, δδδ 
P< 0.001, δ P< 0.05 vs α2-PI1-8-PDGF-BB group, εε P< 0.001 vs α2-PI1-8-VEGF164 group.  
 
 
Newly induced vessels by balanced co-delivery of and α2-PI1-8-
PDGF-BB and α2-PI1-8-VEGF164 are functionally perfused 
 
In order to determine whether newly induced vessels were functionally 
connected to the circulation, their perfusion was assessed by injecting mice 4 
minutes before sacrifice with a fluorescein-labeled tomato lectin (FITC-lectin), 
which binds to the lumen of all vessels connected to the general circulation. 
Perfused endothelial structures were identified by immuno-staining as double-
positive for CD31 and FITC-lectin on frozen sections. As shown in Figures 5 
and 6, essentially all vessels induced both by α2-PI1-8-VEGF164 alone and by co-
delivery of α2-PI1-8-PDGF-BB and α2-PI1-8-VEGF164 were functionally perfused 
after 2 weeks (Fig. 5) and 2 months (Fig. 6). Therefore, balanced co-delivery of 
α2-PI1-8-PDGF-BB and α2-PI1-8-VEGF164 induced the growth of morphologically 
normal and mature vessels that are both stable and functionally perfused. 
 108 
 
Figure 5 Newly Induced vessels by balanced co-delivery of α2-PI1-8-PDGF-BB and α2-PI1-8-VEGF164 
are functionally perfused after 2 weeks. 
FITC-lectin was injected intravenously into mice 4 weeks after gel injection, just before perfusion with PFA 
1% and sacrifice. Muscles cryosections were immuno-stained to detect endothelial cells (CD31, in red), 
while lectin shows in green. Perfused vessels were identified as double-positive for CD31 and FITC-lectin, 
appearing yellow in the merged image. Scale bar = 20 μm 
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Figure 6 Newly Induced vessels by balanced co-delivery of α2-PI1-8-PDGF-BB and α2-PI1-8-VEGF164 
are functionally perfused after 2 months. 
FITC-lectin was injected intravenously into mice 4 weeks after gel injection, just before perfusion with PFA 
1% and sacrifice. Muscles cryosections were immuno-stained to detect endothelial cells (CD31, in red), 
while lectin shows in green. Perfused vessels were identified as double-positive for CD31 and FITC-lectin, 
appearing yellow in the merged image. Scale bar = 20 μm. 
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Short-term co-delivery of α2-PI1-8-PDGF-BB and α2-PI1-8-VEGF164 not 
only normalizes aberrant angiogenesis induced by high α2-PI1-8-
VEGF164 levels, but also increases diameters of morphologically 
normal vessels induced by α2-PI1-8-VEGF164 at a safe concentration 
In order to determine whether the balanced co-delivery of α2-PI1-8-PDGF-BB: 
α2-PI1-8-VEGF164 not only promoted normalization of aberrant angiogenesis 
induced from high α2-PI1-8-VEGF164 levels but also accelerates vascular 
stabilization, we used the same gel composition as previous experiment but 
without aprotinin-α2-PI1-8, thus lasting in vivo around 9 days (Chapter 5). Fibrin 
gels were prepared with two different α2-PI1-8-VEGF164 concentrations, 5μg/ml 
and 50μg/ml, individually or combined with α2-PI1-8-PDGF-BB at 1/20th of the α2-
PI1-8-VEGF164 concentration. After 2 weeks in all conditions the gel was 
completely exhausted. α2-PI1-8-VEGF164 was delivered alone at a concentration 
of 5 μg/ml induced the growth of normal capillaries covered by pericytes (fig. 
7b). Interestingly, quantification of vessel diameters showed that 5μg/ml of α2-
PI1-8-VEGF164 induced vessels significantly larger than negative control (Fig. 7k, 
*** P< 0.001), but co-delivery of α2-PI1-8-PDGF-BB and α2-PI1-8-VEGF164 further 
increased the induced vessels size compared to α2-PI1-8-VEGF164 alone (Fig. 
7k, δδδ P< 0.001), while both having homogenous diameter distribution on the 
range of normal capillaries (Fig. 7 g-i). α2-PI1-8-VEGF164 injected alone at a 
concentration of 50 μg/ml caused the growth of enlarged angioma-like 
structures coated by a thick layer of smooth muscle cells (fig. 7c, asterisks) and 
capillaries devoid of pericytes (fig. 7c, arrows). The balanced co-delivery 
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prevented the growth of aberrant vessels induced from the highest α2-PI1-8-
VEGF164 concentration per se at the highest concentration and promoted the 
maturation of capillaries, which are in this group tightly covered by pericytes (fig. 
7e). 
Quantification of vessels diameters showed that interestingly, the highest α2-PI1-
8-VEGF164 concentration had homogenous vessels distribution in the range of 
normal capillaries, as when co-delivered with α2-PI1-8-PDGF-BB, and rare 
enlarged aberrant vessels (Fig. 7 h-j). This small group of aberrant did not 
increase the 90th percentile towards value characteristic of aberrant 
angiogenesis, indicating the most of the vessels are in the range size of normal 
capillaries (Fig. 7h). Both α2-PI1-8-VEGF164 injected alone or combined with α2-
PI1-8-PDGF-BB induced similar average vessels size, both statistically 
significantly higher than control (Fig. 7, *** P< 0.001). Quantification of the 
amount of induced angiogenesis as vessel length density (VLD), showed that 
the co-delivery of α2-PI1-8-PDGF-BB and α2-PI1-8-VEGF164, when α2-PI1-8-
VEGF164 at a concentration of 5μg/ml, did not significantly increase the amount 
of vasculature induced compared to α2-PI1-8-VEGF164, since both lead about a 
2-fold increase compared to negative control (Fig. 7l *** P< 0.001 vs negative 
control). Both co-delivery of α2-PI1-8-PDGF-BB and α2-PI1-8-VEGF164 when α2-
PI1-8-VEGF164 was at a concentration of 50 μg/ml induced a similar increase of 
vessel length density compared to control without statistical significant 
differences between the two groups (** P< 0.01, * P< 0.05 vs negative control). 
Further investigations are necessary to define if such a short-term co-delivery is 
sufficient to achieve vessels stabilization. 
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Figure 7 Short term co-delivery of α2-PI1-8-PDGF-BB and α2-PI1-8-VEGF164 not only normalize 
aberrant angiogenesis induced by high α2-PI1-8-VEGF164 levels, but also increased diameters of 
morphologically normal vessels induced by α2-PI1-8-VEGF164 at a safe concentration.  
(a-e) Fibrin gels of 50μl volume with inserted two α2-PI1-8-VEGF164 concentration, 5μg/ml and 50μg/ml, 
alone (b and c) or co-delivered with α2-PI1-8-PDGF-BB at 1/20th of the α2-PI1-8-VEGF164 concentration (d 
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and e), were injected into GC muscles of SCID and harvested 2 weeks later after perfusion with PFA 1%. 
Endothelial cells (CD31, in red), pericytes (NG2, in green), and smooth muscle cells (α-SMA, in cyan) were 
immuno-stained on frozen section. Scale bar= 20 μm 
(f-k) Vessel diameters were quantified in each group and their distribution (f, negative control: g-h α2-PI1-8-
VEGF164 groups, i-j α2-PI1-8-PDGF-BB and α2-PI1-8-VEGF164 groups) and average values (μm) (k) were 
calculated. (l) The amount of angiogenesis was quantified as vessel length density (VLD), calculated as 
the ratio between the total vessel length and the area of each measured field (mm/mm2). Results in (k) and 
(l) are shown as mean ± SEM; n = 3 muscles/group; ***, P< 0.001, ** P<0.01 vs negative control, δδδ P< 
0.001, δ P< 0.05 vs α2-PI1-8-PDGF-BB group. Balanced co-delivery of α2-PI1-8-PDGF-BB and α2-PI1-8-
VEGF164 significantly increased the size of vessels induced from the lowest α2-PI1-8-VEGF164 concentration. 
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6.4 Discussion 
Here we showed that balanced co-delivery of α2-PI1-8-PDGF-BB and α2-PI1-8-
VEGF164 by fibrin gel in concentration ratio 1:20 could normalize aberrant 
angiogenesis induced by high α2-PI1-8-VEGF164 levels alone, promoting the 
growth of normal, stable and functional capillaries. Thus, this is a potential 
strategy to reliably induce normal and stable angiogenesis without the need to 
strictly control the α2-PI1-8-VEGF164 concentration. Further, taking advantage of 
this highly flexible tool that allow an easy variation of the growth factors ratio, 
we could assess that α2-PI1-8-PDGF-BB at 1/20th of the α2-PI1-8-VEGF164 
concentration is the minimum concentration necessary to normalize aberrant 
angiogenesis. This ratio was validated using a second higher α2-PI1-8-VEGF164 
concentration, confirming that absolute levels of the two growth factors were not 
important as the relative dosage present in the microenviroment of the growing 
vessels. It is relevant the definition that a 5-fold less amount of α2-PI1-8-PDGF-
BB compared to what previously defined using cell-based and viral gene 
delivery (10) is sufficient to prevent the loss of pericytes and convert vascular 
remodeling into a network of mature homogenous capillaries. However, further 
investigations are necessary to identify if the reducing of α2-PI1-8-PDGF-BB from 
1/3rd to 1/20th, which did not affect the normalization effect, had an effect on the 
vessel size and amount of induced vasculature. 
After 2 months, α2-PI1-8-VEGF164 injected alone induced only normal and mature 
capillaries, as when co-delivered with α2-PI1-8-PDGF-BB and in contrast to the 
aberrant vessels induced after 2 weeks. However, the balanced co-delivery of 
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α2-PI1-8-PDGF-BB and α2-PI1-8-VEGF164 produce vessels significantly larger 
than those induced from α2-PI1-8-VEGF164 injected alone. These results can 
have an impact on the therapeutic potential of the system, as others and we 
have previously found that the size of newly induced vessels is key to determine 
the efficacy of therapeutic angiogenesis approaches (19, 20). 
The normalization potential of α2-PI1-8-PDGF-BB was maintained even when we 
did not use aprotinin-α2-PI1-8 and thus growth factor release was accelerated. 
Further, in this gel composition, α2-PI1-8-PDGF-BB increased vessels size 
induced by α2-PI1-8-VEGF164 alone when α2-PI1-8-VEGF164 was at a 
concentration of 5 μg/ml, which per se induced normal angiogenesis. This 
potentially could improve the therapeutic efficacy of this α2-PI-1-8-VEGF164 
concentration that per se induces normal angiogenesis, since, as discussed 
above, newly induced vessels size is determinant for therapeutic efficacy in 
ischemia (19, 20). 
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6.5 Conclusions and future perspectives 
In conclusion, with this work we demonstrated that controlled co-delivery of α2-
PI1-8-VEGF164 and α2-PI1-8-PDGF-BB proteins is a convenient, safe and 
clinically applicable approach to expand the range of VEGF doses within which 
normal and stable angiogenesis can be reliably and efficiently induced. 
Additionally, co-delivery of α2-PI1-8-PDGF-BB and α2-PI1-8-VEGF164 when is at a 
low concentration which per se induced safe angiogenesis is a strategy to 
potentiate the possible therapeutic effect by increasing induced vessels size. 
Further analyses are ongoing to determine the minimum duration of factor co-
delivery necessary to achieve vessel stabilization and indefinite persistence, in 
order to define a complete set of parameters (dose, ratio and duration) for 
clinical application. 
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7. Summary and future 
perspectives 
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Therapeutic angiogenesis, which aims to stimulate the growth of new capillaries 
from pre-existing ones to increase blood supply and support tissue function and 
recovery, is a promising strategy both for treating ischemic diseases and 
support engraftment and survival of transplanted engineered tissues(1, 2). 
VEGF-A is the master regulator of angiogenesis (3) and thus it has been tested 
in several clinical trials, but with disappointing results(4). 
In this work, we aimed to establish an optimized platform to induce stable and 
functional angiogenesis in relevant target tissues using recombinant proteins 
engineered to covalently bind to fibrin gel. In the fifth chapter, we demonstrated 
that delivery of α2-PI1-8-VEGF164 from fibrin gels is a suitable system to induce 
angiogenesis in skeletal mouse muscle tissues. The optimization of the different 
parameters influencing the effective delivered dose of α2-PI1-8-VEGF164 and the 
duration of the α2-PI1-8-VEGF164 release, such as the fibrin gel composition and 
the concentration of the plasmin inhibitor aprotinin-α2-PI1-8, allowed us to reliably 
induce exclusively normal and mature micro-vascular networks, which were 
stable and functionally perfused, over a very wide range (at least 500-fold) of 
α2-PI1-8-VEGF-A164 concentrations. Remarkably, newly induced vessels did not 
regress for at least 3 months, whereas the injected gels were almost completely 
degraded by 4 weeks, demonstrating that they achieved independence from 
exogenous VEGF signaling for their survival and suggesting that they could 
likely persist indefinitely. This is particularly relevant for the therapeutic potential 
of this approach, since until now one of the main limits of recombinant protein 
delivery for therapeutic angiogenesis has been the insufficient duration of GF 
release to achieve stable and persistent effects(5). 
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The flexibility of the fibrin-bound delivery platform allowed us to define an 
extremely wide range of VEGF doses that efficiently induce angiogenesis, 
including those determining the transition between normal and aberrant vessels, 
which is a key feature for the design of preclinical dose-escalation studies.  
The concentration of α2-PI1-8-VEGF164 did not influence the amount of induced 
vasculature, which was maximal already with the minimum concentration and 
was maintained over a 500-fold range. Nevertheless, the concentration of α2-
PI1-8-VEGF164 influenced the size of induced vessels, which remained 
unaffected by concentrations up to 0.1 μg/ml, but was significantly increased by 
5 μg/ml. These results are relevant for the therapeutic potential of α2-PI1-8-
VEGF164 delivery, as others and we have previously found that the size of newly 
induced vessels is key to determine the efficacy of therapeutic angiogenesis 
approaches(6, 7). Based on these considerations, we chose a concentration of 
2 μg/ml to test the ability of fibrin-bound α2-PI1-8-VEGF164 delivery to induce 
functional improvement in an ischemic wound-healing model. The treatment 
with α2-PI1-8-VEGF164 stimulated a significant increase in normal angiogenesis, 
which significantly improved tissue perfusion and wound closure in ischemic 
conditions, restoring healing in ischemia to non-ischemic levels (36% still open 
wound size by 7 days), thereby demonstrating that α2-PI1-8-VEGF164 from an 
optimized fibrin platform induced functional improvement in an ischemic model. 
These promising results warrant a preclinical evaluation of the therapeutic 
potential of this approach. The first step will require the comparison of several 
α2-PI1-8-VEGF164 concentrations, in the range that proved able to induce normal 
and stable angiogenesis in healthy muscle, for their functional effects in a pre-
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clinical model of hind limb ischemia, in order to define the actual therapeutic 
window. In fact, it has been previously shown that differences in the size of 
induced vessels may produce significant disparities in therapeutic efficacy (6, 
7)and a range of lower doses, which did not show any increase in vessel size, 
may prove inefficacious. The second step should then focus on the obvious 
differences between rodents and human patients suffering from ischemic 
diseases, including physiology, body size and distance over which collateral 
arteries need to grow, using more relevant large animal models (2). 
In the sixth chapter, we determined that balanced co-delivery of α2-PI1-8-PDGF-
BB and α2-PI1-8-VEGF164 from fibrin hydrogels had the potential to normalize 
aberrant angiogenesis induced by high α2-PI1-8-VEGF164 alone, while also 
achieving long-term stability. Therefore, this approach provides a tool to expand 
the range of α2-PI1-8-VEGF164 doses within which normal and stable 
angiogenesis can be reliably induced. Further, taking advantage of the robust 
flexibility of this platform, we could determine, with two different α2-PI1-8-
VEGF164 concentrations, that complete normalization of induced angiogenesis 
was ensured by a ratio of α2-PI1-8-PDGF-BB: α2-PI1-8-VEGF164 as low as 1:20, 
which is 5-fold lower than the ratio previously defined using cell-based and viral 
gene delivery (8). Interestingly, co-delivery of α2-PI1-8-PDGF-BB and α2-PI1-8-
VEGF164 produced significantly larger vessels than the same dose of α2-PI1-8-
VEGF164 alone, which could have significant therapeutic implications, since, as 
discussed above, vessel size is the main determinant of therapeutic efficacy in 
ischemia(6, 7). 
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α2-PI1-8-PDGF-BB co-delivery not only increased the size of vessels induced by 
α2-PI1-8-VEGF164 alone, but also significantly accelerated vascular stabilization, 
thereby allowing persistent angiogenesis to be generated by fibrin gels with a 
duration as short as 2 weeks, thereby providing a strategy to potentiate both the 
therapeutic efficacy and the safety of α2-PI1-8-VEGF164 alone. 
Further investigations will be needed in order to rigorously determine the 
minimum duration of growth factor co-delivery necessary to achieve vessel 
stabilization and indefinite persistence, to define a complete set of parameters 
(dose, ratio and duration) for therapeutic applications. 
The optimized platform that was developed in the work here described proved 
also to be a flexible tool for investigating the cellular and molecular mechanisms 
of VEGF dose- and time-dependent angiogenesis, thanks to its high tunability 
that allowed us to finely and precisely control VEGF dose over an extremely 
wide range of concentrations. For instance, our group has previously found, 
using myoblast-mediated gene delivery, that VEGF over-expression in skeletal 
muscle at the doses required for therapeutic benefit induces angiogenesis by 
intussusception rather than by sprouting (9). However, using the cell-based 
platform it was not possible to investigate whether the induction of 
intussusceptive angiogenesis rather than sprouting was a function of VEGF 
dose or a tissue-specific feature of muscle vascular networks. Initial 
observations we recently obtained with the fibrin-bound platform confirmed that 
higher concentrations of α2-PI1-8-VEGF164 induce vascular enlargement and 
splitting (intussusception) around the implanted gel. However, reducing 
sufficiently the α2-PI1-8-VEGF164 concentration caused a switch in the mode of 
	
   124	
  
angiogenic growth to sprouting inside the gel, suggesting that VEGF dose and 
gradient shape in the microenvironment dictate the endothelial cell fate decision 
whether to sprout or to split. Based on these results, the flexibility of this 
platform is expected to provide valuable insights in the molecular mechanisms 
underlying the dose-dependent angiogenic response to therapeutic VEGF over-
expression in skeletal muscle. 
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February 2006-July 2006 Internal training as undergraduate student 
University of Siena, Department of Molecular Biology, Laboratory of Molecular 
Biotechnology, Supervisor Prof Luisa Bracci & Dr Chiara Falciani 
1, Via Fiorentina, 53100 Siena, Italy 
 
Research project: synthesis and characterization of tetrabranched peptides for 
tumor targeting, in order to develop proteases- resistant peptides highly specific 
for several tumors applicable as carriers for chemotherapeutics agents and 
tumor-imaging compounds.   
 
Mother tongue Italian 
 
Other language  English (Speaking: Good; Writing: Good; Reading: Good) 
 
Technical skills and 
competence 
Fibrin gel preparation for in vitro assay and in vivo injection as liquid in hind limb skeletal 
mouse.  
 
Immunohistochemistry, immunofluorescence techniques and imaging by confocal microscopy 
(Carl Zeiss LSM 710 controlled via the ZEN software utility)  
 
Cell culture handling in conventional monolayer  
 
Cell transfection and transduction (with retrovirus)  
RNA, DNA & Protein extraction, quantitative real time PCR 
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PUBLICATIONS LIST 
 
Sacchi, V., Mittermayr, R., Hartinger, J., Martino MM, Lorentz KM, Morton T., Hofmann A., Wolbank S., Largo R., 
Marshall J., Groppa E., Gianni-Barrera R., Ehrbar M., Hubbell JAH, Redl H., Banfi A. Sustained and highly tunable 
delivery of recombinant VEGF164 from optimized fibrin matrices ensures normal, stable and functional 
angiogenesis (Proceedings of the National Academy of Sciences, 2014 May 13;111(19): 6952-7).  
 
Sacchi V., Martino MM, Gianni-Barrera R., Hubbell JAH, Banfi A. Recombinant PDGF-BB and VEGF164 balanced co-
delivery from fibrin gels normalizes aberrant angiogenesis induced by high VEGF164 concentration (manuscript in 
preparation).  
 
Groppa E., Brkic S., Sacchi V., Trani M., Muraro M.G,, Heberer M., Banfi A. EphrinB2/EphB4 signaling controls the 
switch from normal to aberrant angiogenesis caused by VEGF dose (manuscript in preparation).  
 
Bichet S., Fogli B., Sacchi V., Heberer M., Banfi A., Gianni-Barrera R. Sustained activation of Notch4 by Jagged-1 
correlates with aberrant angiogenesis induced by VEGF in skeletal muscle (manuscript in preparation).  
 
PARTECIPATION AT CONFERENCES AND SYMPOSIA 
 
Oral 
Presentation 
Recombinant PDGF-BB and VEGF164 balanced co-delivery by fibrin gels normalizes aberrant 
angiogenesis induced by high VEGF164  concentrations. Tissue Engineering and Regenerative Society, 
Annual EU Meeting, Genoa 2014 
 
Sustained and highly tunable delivery of recombinant VEGF164 from optimized fibrin matrices ensures 
normal, stable and functional angiogenesis. Tissue Engineering and Regenerative Society, Annual EU 
Meeting, Istanbul, Turkey (2013). 
 
Dose and time-dependent angiogenesis by controlled delivery of matrix-bound VEGF. Tissue 
Engineering and Regenerative Society, Annual EU Meeting, Granada, Spain (2011).  
 
 
Bacteria culture and cloning 
 
ELISA & Western Blot 
 
In vivo experiments (with mice) 
 
Cytofluoremetric analyses with BD FACS Calibur  
 
Purification of Nucleotides and Peptides by HPLC chromatography 
 
Computer skills and 
competence 
OS: Windows and Macintosh 
 
Good command of internet and Microsoft Office tool, in particular Word, Power Point, Excel, 
and Access. 
 
GraphPad Prism 5.0, Adobe Photoshop CS5, ImageJ and FlowJo. 
 
Social skills and 
competence 
Able and ready to work both independently as well as in team  
 
Hard-worker with very strong determination and passion 
 
High organizational capacity in- and outside work 
 
High ability and adaptability to new working and social environments 
 
Driving licence Italian driving licence, category B 
 
Work Permit B permit for Switzerland 
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Poster 
Presentation 
Recombinant PDGF-BB and VEGF164 balanced co-delivery by fibrin gels normalizes aberrant 
angiogenesis induced by high VEGF164  concentrations. American Society of Cell and Gene Therapy, 
Washington 2014.  
 
Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained 
delivery of recombinant VEGF164. 3
rd
 Cardiovascular and metabolic research conference, Fribourg, 
Switzerland (2013) 
 
Recombinant PDGF-BB and VEGF164 balanced co-delivery by fibrin gels normalizes aberrant 
angiogenesis induced by high VEGF164  concentrations. Tissue Engineering and Regenerative Society, 
Annual EU Meeting, Istanbul, Turkey (2013). 
 
 Sustained and highly tunable delivery of engineered VEGF164 from optimized fibrin matrices ensures 
normal, stable and functional angiogenesis. 9
th
 Swiss Stem Cells Network, Bern, Switzerland, (2013) 
 
 Dose and time-dependent angiogenesis by controlled delivery of matrix-bound VEGF. Tissue 
Engineering and Regenerative Medicine Society, 3
rd
 World Congress, Vienna, Austria  
 
Dose and time-dependent angiogenesis by controlled delivery of matrix-bound VEGF Frontiers in Cardiac 
and Vascular Regeneration, Trieste, Italy (2012). 
 
 
 
 
Dose and time-dependent angiogenesis by controlled delivery of matrix-bound VEGF.  8
th
 International 
Symposium on the Biology of Endothelial Cells, Zurich, Switzerland(2011). 
 
 
ADDITIONAL INFORMATIONS 
 
Personal interests Travelling, Reading, Enjoy with friends 
 
Sports Swimming, Biking, Skiing, Volleyball, Hiking 
 
REFERENCES: 
 
- PD, Dr Andrea Banfi: andrea.banfi@usb.ch 
- Prof Heinz Redl: Office@TRAUMA.LBG.AC.AT 
- Dr Enrico Balducci: enrico.balducci@novartis.com 
- Prof Lorenza Trabalzini: trabalzinil@unisi.it 
- Dr Edward Dudley: e.dudley@swansea.ac.uk  
 
